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Abstract
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has co-evolved
with humans since the dawn of our species. Despite advances in antibiotic therapy, TB
global burden is till enormous. Antimicrobial resistance and HIV epidemic challenge the
ongoing efforts to control TB. Novel anti-TB agents are required to address the issues
associated with current drug regimens and to improve the outcomes of TB therapy. In this
work, we have evaluated the antimycobacterial activity of propargyl-linked antifolates
against drug-susceptible and drug-resistant M. tuberculosis. Antifolates exerts their
antimicrobial effect by interruption of folate biosynthetic pathway and one-carbon
metabolism. We have successfully identified a few novel antifolates with potent
antimycobacterial activity. Through comparison of these compounds with paraaminosalicylic acid, a second-line anti-TB agent, we were able to elucidate the
mechanism of action of both. Finally, we have shown that these compounds are also
potent inhibitors of M. avium complex, another group of pathogenic Mycobacteria. We
suggest that propargyl-linked antifolates are excellent candidate for future drug
development as antimycobacterial agents.
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1
1.1

Tuberculosis
Historical Background

Consumption, phthisis and the White Plague are all names used to refer to tuberculosis
(TB). Regardless of the name, TB has been a scientific puzzle, as well as an economic
and social problem that has claimed millions of lives throughout history. The change of
human lifestyle from small hunter-gatherer groups to larger permanent settlements
provided an ideal niche for the emergence of many infectious diseases including TB. TB
has travelled with mankind since the Neolithic era and early Mediterranean civilizations.
Assyrian clay tablets from the 7th century B.C. document patients with TB symptoms and
coughing blood.1 During the Renaissance, TB was one of the most common diseases in
Europe and by the end of the 17th century it gained the title of “the robber of the youth”,
infecting those at every level of the socioeconomic hierarchy. With the migration of
Europeans, TB spread to the New World, traveling faster than the explorers. Fueled by
industrial revolution, urbanization, and poverty, TB reached its heyday in the early 1800s
and even became a cultural icon of the 19th century, inspiring many works of art.2
Isolation and identification of Mycobacterium tuberculosis (Mtb) by Robert Koch in
1882 marked a turning point in the understanding of TB and put an end to the struggle
among medical practitioners and scientists about the etiology of this deadly disease. The
work of Koch, Jean-Antoine Villemin, Clemens von Pirquet and others led to the
development of the skin tuberculin test which remains the most common diagnostic tool
for latent and active TB infection. Soon after, Paul Ehrlich, a young physician at the Berlin
Charité hospital, developed a staining method to visualize tubercle bacilli in the
surrounding tissues using aniline water, fuchsin and gentian-violet. Introduction of

1

carbolic and sulfuric acid by Franz Ziehl and Fredreich Neelsen, respectively, further
improved this method into a standard procedure to identify Mycobacteria. Today, this
staining method is called Ziehl-Neelsen or acid-alcohol fast stain.
Owing to advances in the knowledge of TB, along with improved social and living
conditions, TB tidal wave started to decline in the mid-19th century. Another reason for
this decline was understanding the contagious nature of this disease and establishment
of sanatorium for the isolation of TB sufferers. In early 20th century, Albert Calmette and
Camille Guérin from Pasteur Institute developed Bacillus Calmette-Guérin (BCG) vaccine
against TB which was used to immunize more than 100,000 children. But World War I
and II allowed the resurgence of TB. In post-war years, a herculean effort made by
UNICEF, World Health Organization (WHO) and Danish Red Cross, based on tuberculin
test and BCG vaccination, led to the screening of 30 million and vaccination of 14 million
people. Policy guidelines for TB issued by WHO Expert Committee resulted in a dramatic
decline of the disease in the next few decades.2,3

1.2

The Global Burden of TB

Despite the progress in controlling the disease and reducing the mortality rate, TB global
burden is still enormous. Currently, TB is the leading cause of death from a single
infectious agent. The burden of TB can be measured in terms of incidence, prevalence,
and mortality. According to WHO annual reports, there were an estimated 10.4 million
new cases of TB and 1.3 million deaths worldwide in 2016. Pediatric tuberculosis
comprised 6.9% of these cases. There were also an additional 374,000 deaths among
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HIV-positive people.1 56% of the estimated number of incident cases occurred in India,
Indonesia, China, the Philippines and Pakistan. Other high TB burden countries with
declining incidence rate includes Ethiopia, Kenya, Lesotho, Namibia, the Russian
Federation, the United Republic of Tanzania, Zambia and Zimbabwe.4,5 In the United
States, Centers for Disease Control and Prevention (CDC) has estimated a total of 9,272
TB cases in 2016.6
The global case fatality ratio (CFR) of TB was 16% in 2016. The CFR exceeds 20% in
WHO African Region suggesting existing barriers and inequalities in access to TB
diagnosis and treatment.4 Complex immunological responses, old and inadequate
diagnostics and treatments, multidrug-resistant (MDR)-TB and HIV co-infection are a few
of the many challenges to the global control of TB.7

1.3

Mycobacterium tuberculosis

M. tuberculosis and M. leprae are the most famous members of the genus Mycobacterium
and responsible for two lethal contagious diseases, TB and leprosy, respectively. Mtb,
also called Koch’s bacillus, is one of the most successful human pathogens infecting onethird of the world populations. Part of this success is due to the ability of this obligate
microorganism to survive in the latent form within the host macrophages. One of the
unusual features of Mtb that deserves special attention is its highly impermeable cell wall
that confers many of the unique characteristics of this microbe.8

1

When an HIV-positive person dies from TB, the underlying cause is classified as HIV in the international classification of disease

system (ICD-10).
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1.3.1 The Architecture of Mycobacterial Cell Wall
The mycobacterial cell wall is essential for growth, survival and virulence. This waxy cell
wall is also the first-line of defense against antibiotics and equips the cell with an inherent
resistance to many therapeutic agents. The Mtb cell wall is made of an inner layer and an
outer layer encircling the plasma membrane (Figure 1.1). 9

Figure 1.1. Cell wall of Mycobacterium tuberculosis (borrowed from Nature Reviews Microbiology)

Although the existence of an outer lipid bilayer in Mycobacterium was suggested a long
time ago, its structure was unknown for decades. By use of cryo-electron tomography
(CET)10 and electron microscopy of thin cryosections11, now we know that mycobacterial
outer membrane is approximately 8 nm thick and is morphologically symmetrical. In
addition to long- and short-chain fatty acids, this layer consists of different
4

polysaccharides

including

lipoarabinomannan

(LAM),

lipomannan,

phthiocerol

dimycocerosate, Mtb-specific phospholipids and phosphatidylinositol mannosides.12
Another important glycolipid of the outer membrane is dimycolyl trehalose, also known as
cord factor, which causes the Mtb to grow in serpentine cords in vitro. Cord factor is
essential for the evasion of the host immune system by Mtb cells (section 1.4.2).13 The
components of outer membrane are the main players in host-pathogen interactions and
cell signaling.
The mycobacterial inner layer is a thick tripartite structure consisting of a peptidoglycan
layer (PG), an arabinogalactan layer (AG) and mycolic acids (MA) covalently linked
together. This PG-AG-MA complex is the essential core of the mycobacterial cell wall.8
PG. This polymer, made of sugars and amino acids, provides extendible strength
against osmotic pressure while still allowing for growth and expansion. The glycan strand
is formed by two alternating amino sugars N-acetylglucosamine (NAG) and Nacetylmuramic acid (NAM), linked together by a b-(1,4)-glyosidic bond. NAMs are
attached to the tetrapeptide L-alanyl-D-isoglutaminyl-meso-diaminopimelyl (DAP)-Dalanine. This peptide chain is cross-linked to other peptide chains via a mixture of 3à3
DAP-DAP and 3à4 DAP-D-Ala linkages. These cross-linkages give a strong, mesh-like
arrangement to the PG layer and provides bacteria with shape, rigidity, and protection
from turgor pressure within the cells that pushes the plasma membrane to the cell wall.
In Mycobacterium, 70-80% of the PG layer is reinforced by cross-linkages, in contrast to
50% in Escherichia coli.8,9
AG. This layer is made of repeating D-arabinan and D-galactan, both in an uncommon
furanose form (D-galactofuranosyl or Galƒ and D-arabinofuranosyl or Araƒ). The galactan
5

unit is approximately 30 linear alternating b (1à5) and b (1à6) Galƒ residues synthesized
by the galactofuranosyl transferases Glf, GlfT1 and GlfT2. D-arabinan consists of three
motifs of 22 Araƒ residues synthesized by DprE1 and DprE2 and arabinofuranosyl
transferases AftA, EmbA, EmbB, and AftB. The arabinan unit is attached to the C5
hydroxyl group of b (1à6)-linked Galƒ units, specifically to the 8th, 10th and 12th residues.
AG is covalently tethered to 10-20% of the NAM residues of PG via a phosphoryl-Nacetylglucosaminosyl-rhamnosyl linkage. 9,14
MA. This layer is the key determinant of cell wall permeability and fluidity. It is made of
short a-alkyl and long b-hydroxyl fatty acids ranging from 60 to 90 carbon per chain.
MAs are synthesized via multi-enzymatic cascade reactions. Fatty acid synthase I (FASI)
provides the alkyl branch of the mycolic acid. FASI product is transferred to FASII where
the meromycolate backbone is made. The meromycolate backbone of these fatty acids
appears in three different types: a-meroacids, methoxy-meroacids, and keto-meroacids
varying in the level of saturation, cyclopropanation, and oxygenation. Numerous
cyclopropane synthases decorate the meromycolate with functional groups. Polyketide
synthase Pks13 catalyzes the condensation reaction between the alkyl branch and the
meromycolate chain. Finally, the enzyme corynebacterineae mycolate reductase A
(CmrA) performs the last reduction and generates MA. MmpL inner membrane
transporter transfers MA chains to the cell surface where FbpABCD complex (antigen 85)
ligates them to the AG layer.15
Considering the role of lipids in augmenting the mycobacterial cell wall, it is not
surprising that 30% of the Mtb genome is dedicated to lipid synthesis and metabolism.
This elaborate cell wall limits the uptake of nutrients and is in part responsible for the slow
6

growth rate of this pathogen (doubling time of 18-24 hours). The complexity of this cell
wall also challenges cell elongation, division, and chromosome segregation requiring the
pathogen to develop special mechanisms to meet these needs.
1.3.2 Cell Growth and Division
The continuity of life depends on the ability of cells to reproduce and generate viable
progeny capable of autonomous function. Bacterial cell division and proliferation can be
divided into two main phases: elongation of the mother cell and its division into daughter
cells (birth).14
Elongation. This phase involves chromosome replication and segregation which
demands a large amount of cellular resources and is therefore mainly controlled by
nutrient availability. Replication starts by the binding of the initiator protein DnaA, to the
origin of replication, OriC, and ends by arriving of the replication machinery at the
termination sequence, ter. Chromosome segregation, which ensures the separation and
translocation of sister chromosomes, marks the end of the elongation stage.8,16
Division. This step is recognized by cytokinesis, the event that partitions the mother
cell by separating the cytosolic contents to generate progeny cells with identical genetic
material. Cytokinesis triggers the formation of divisome complex, a massive multiprotein
assembly recruited to the middle of the cell to generate the division septum. The tubulinlike protein FstZ is the first participant of this assembly gathered at mid-cell. By
hydrolyzing guanosine triphosphate (GTP) molecules and cluster them into filaments,
FstZ forms a ring-like structure known as Z ring. Z ring determines the sitinge of septation
and summons the proteins required for the synthesis of septal PG and cell wall
constriction. The rate of polymerization activity of FstZ protein in Mtb is 20-fold lower than
7

its homologue in E. coli, suggesting its contribution to the slow growth rate of Mtb.8 As the
sisters grow apart, the septum must cleave to physically separate the cells. In
Mycobacteria, peptidoglycan hydrolase RipA and resuscitation promotion factor B (RpfB)
are the hydrolases responsible for the cleavage of nascent septal PG and splitting the
progenitor.8,14,16
Retaining the fundamentals, bacteria have evolved different patterns of cell growth and
division. The two most common types are dispersed and zonal growth. In dispersed
mode, utilized by E. coli and Bacillus subtilis, bacteria add the new cell wall material along
most of the cell envelope. The zonal pattern of growth is defined by the insertion of
nascent cell wall to specific regions of the cell. Many rod-shaped bacteria follow a type of
zonal growth limited to one or two poles (polar growth). These bacteria contain an old
pole that is inherited from the mother cell and a new pole which is synthesized during
division. Utilizing a symmetric division, they produce two daughter cells of equal size.17
Mycobacteria is unique in its tendency to grow only from the older pole. Following this
unipolar fashion, Mycobacteria face an asymmetric division which produces daughter
cells that despite sharing the same genome, vary in size, growth rate and cell wall
composition. The longer cell which inherits the old pole (accelerator) grows faster
compared to its smaller sister that must generate a new pole (alternator). As the new pole
matures, cells grow faster and longer. On the other hand, the old pole in accelerator cells
slows down after a few generations.8,18
This asymmetric pattern of growth and division leads to intrinsic heterogeneity in
mycobacterial populations which plays an important role in the pathogenicity of the
microbe and the host-pathogen interactions.19 One of the significant outcomes of
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heterogeneity in microbial populations is different susceptibility to antibiotics. For
example, mycobacterial alternator cells shown to be less susceptible to the cell wall
synthesis inhibitors meropenem and cycloserine, but

are more susceptible to the

transcription inhibitor rifampicin.18

1.4

Host-Pathogen Interactions

The successful establishment and maintenance of an infection is determined by the ability
of the pathogen to survive, proliferate, and persist within the infected cells. To promote
this lifestyle, bacteria have evolved elaborate countermeasures to thwart innate immunity.
Mtb is an excellent example of a manipulator pathogen that overturns the host immune
system for its survival. Persistence of Mtb in human depends on its ability to survive within
the host macrophages. This intimate connection reflects the co-evolutionary balance that
the host and pathogen has reached to secure their survival.
1.4.1 Co-evolution of Mtb and Homo sapiens
Host-pathogen co-evolution is the adaptive genetic change of the pathogen and its host
due to the reciprocal selective pressure that they place on each other. To comprehend
the pathogenicity of Mtb and its interactions with the host environment, it is important to
understand TB from a co-evolutionary perspective.
A thorough mitochondrial population genomics study has shown that MTB complex
(MTBC), including Mtb and seven other species and subspecies, emerged ~70,000 years
ago and accompanied the migration of anatomically modern human out of Africa. This
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study also showed a striking similarity between the mitochondrial genome of MTBC and
human, confirming evolution of MTBC in parallel with its human host.20
Until recently, it was generally accepted that Mtb evolved from M. bovis, a member of
MTBC that causes TB in cattle. It was hypothesized that human acquired TB from cattle
during the domestication of farm animals in the Fertile Crescent around 10,000 years ago.
This region, bounded by the Mediterranean Sea and Persian Gulf, was a cradle of
agriculture that enabled people to live in close proximity and provided a perfect
environment for a respiratory pathogen like Mtb to thrive. Over the years, this hypothesis
obtained the status of fact as Jared Diamond in Guns, Germs and Steel calls TB “the
lethal gift of livestock”. But recent comparative genome analysis has indicated that Mtb
is more closely related to the ancestor of the complex than it is to M. bovis.21 Changes in
human demography are likely the reason for the divergence of Mtb from this ancestor
strain. Genome sequencing has shown that M. bovis has a smaller chromosome
comparing to Mtb. Considering that MTBC is a clonal population and do not show
horizontal gene transfer, this smaller chromosome suggests deletions in the M. bovis
genome, not insertions in Mtb. This means that either Mtb infected bovine and led to the
divergence of M. bovis, or Mtb and M. bovis evolved in parallel from the common ancestor
of the complex.20,21
Investigating the evolutionary success of Mtb and its adaptation to the host environment
over time may aid in predicting future patterns of the disease and design of new
diagnostics and therapeutics to bring an end to this historic partnership.
An interesting example comes from studies that showed modern TB strains, such as
the Beijing TB lineage, are associated with accelerated progression to active disease
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compared to their ancient ancestors with a longer latency period. This phenomenon is a
result of the adaptation of modern strains to larger and populous societies where there is
no worry for this obligate pathogen to kill off its host population.22 This worrisome finding
means that Mtb is evolving toward more aggressive strains with shorter latency.
1.4.2 Immunopathology of TB
The human immune response to TB is a complex reaction that involves a wide variety of
immune cells and inflammatory mediators. Understanding the immunopathology of TB
has been a scientific challenge due to the host lack of success in eradication of the
infection despite the development of appropriate immune responses. The hallmark of TB
infection is formation of granulomas in the lungs. Each granuloma is a unique battlefield
that contains the infection but also allows the bacteria to survive and persist. The
immunological life cycle of TB can be divided into three interrelated stages: primary
infections, latency and reactivation.
Stage 1: Primary infection. The infection begins by the inhalation of Mtb-containing
aerosol droplets. Travelling through the respiratory system, Mtb ends up in lung alveoli
where it is phagocytosed by alveolar macrophages.23 Macrophages, the frontier soldiers
of innate immunity, engulf and digest inhaled particles resulting in degradation, clearance
and presentation of antigens to adaptive immune cells. Phagocytosis is associated with
the formation of a large internal vesicle called phagosome. To degrade the pathogen,
phagosomes deliver their cargo to lysosomes, dynamic organelles that receive and
degrade macromolecules from endocytic, phagocytic, and autophagic pathways. Upon
fusion with lysosomes, phagosomes acidify to pH below 5.0 within 10-12 minutes. This
acidic environment inhibits bacterial activity while optimizing the activity of lysosomal
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hydrolytic enzymes.24 However, phagocytosis by macrophages is not the end of the Mtb
life cycle. Mycobacteria have evolved different mechanisms to survive within the
macrophages including triggering anti-inflammatory responses and arresting the
maturation of phagosomes to keep them as a habitable milieu. Mtb prevents phagosomelysosome fusion by interrupting the acidification of phagosomes. Studies have shown that
Mtb arrests phagosomes at an early non-acidified stage at pH 6.4, considerably higher
than lysosomal pH 4.5-5.0.25 Although the details of these events are left to be
understood, it is confirmed that the glycolipids of the Mtb cell wall confer survival
advantages to the pathogen by blocking normal host trafficking events.26 Pathogenic
mycobacteria also employ eukaryotic-like signal transduction mechanisms to modulate
host cell trafficking pathways. Protein kinase G (PknG), a eukaryotic-like serine/threonine
protein kinase found in Mtb, has been shown to be essential for the survival of the
pathogen within macrophages. Furthermore, a tetrahydrobenzothiophene PknG inhibitor
was able to halt the growth of Mtb within macrophages in a dose-dependent manner.27
Although primary TB infection follows a relatively reproducible course, it is important to
remember that the genetics of the host and also the pathogen plays a crucial role in the
extent of the initial immune response.23
Stage 2: Granuloma formation and latency. This stage is characterized by the
emergence of cell-mediated immunity and development of granulomas. Mtb, escaped
from the bactericidal effects of alveolar macrophages, triggers the infected cells to invade
the subtending epithelium. Production of tumor necrosis factor (TNF)-a and inflammatory
chemokines recruit neutrophils, natural killer (NK) T cells, CD4+, and CD8+ T cells to the
site of inflammation. These cells produce and release a variety of inflammatory cytokines
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such as interleukins. Cell wall lipids including mono- and di-mycolate trehalose also play
a significant role in the recruitment of monocytes and induction of chemokines. This
inflammatory response is controlled and down regulated by interferon (IFN)-g that allows
the formation of stable granuloma. At this point, the granuloma is a necrotic core of
infected macrophages surrounded by a dense wall of foamy macrophages2 and giant
cells3. Mature granulomas also show extensive neovascularization and develop a fibrous
cuff of extracellular matrix. This stratified structure is responsible for the containment of
the pathogen during latent infection.25,26,28,29 During latency, there is no apparent sign of
the disease and the infection is not transmissible. The dominant environmental factor that
controls TB latency is hypoxia. Dormancy in Mtb is also regulated by a set of
approximately 50 genes called dormancy regulon (DosR).30 Studies have shown that
dormant Mtb responds very quickly to stimulants such as oxygen exposure and fresh
media suggesting that quiescent Mtb is lurking around, waiting for an opportunity to
reactivate.31
Stage 3: Reactivation. Latent TB can progress to the active form by any condition that
affects the quantity and quality of CD4+ T cells including HIV infection, advanced age,
malnutrition, and stress. Other risk factors for developing active TB includes diabetes
mellitus, treatment with glucocorticoids, silicosis, and hematological malignancies. In a
situation like this, granulomas decay into a structureless mass of cellular debris
(caseation), rupture and release thousands of live bacilli into airways full of fresh oxygen.

2

A macrophage loaded with lipid droplets and often found in persistent infections such as chlamydia, toxoplasmosis and TB.

3

A giant multinucleate cell formed by fusion of macrophages.
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Mtb escape from granulomas results in the development of a productive cough and
clinical manifestation of the disease.26,28

1.5

Clinical Manifestation and Diagnosis

TB manifestation depends on several factors including age, immune status, co-existing
diseases, immunization history and the virulence of the pathogen. Although primarily
considered as a pulmonary disease, TB can also exist in extrapulmonary forms due to
dissemination of the pathogen throughout the body.
In pulmonary TB, symptoms are usually gradual in onset and aggravate as the disease
progress. Cough is the most common presentation accompanied by fever, night sweats,
and weight loss. The most common haematological manifestations are increases in the
peripheral blood leukocyte count and anaemia. Different types of pulmonary TB include
parenchymal, endobronchial, and intra-thoracic lymph node infections.
Extrapulmonary TB can exist in many different fatal forms including pleural, miliary,
extra-thoracic lymph node, central nervous system (TB meningitis), spinal, arthritis,
urogenital and laryngeal infections.
Common diagnostic tools are tuberculin skin test, IFN-g release assay, chest
radiography, sputum smear microscopy, and culture-based methods. Diagnosis of
extrapulmonary TB is more challenging and requires additional techniques such as
biopsy, computed tomography (CT), and magnetic resonance imaging (MRI). Upon
positive diagnosis, TB needs to be treated to prevent life-threatening damages to different
parts of the body and to control the transmission of the disease.
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1.6

TB Treatment

In 1943, almost 60 years after the discovery of tubercle bacillus, discovery of streptomycin
by Selman Waksman at Rutgers University, NJ made a significant breakthrough in
fighting TB which was almost a death sentence at the time. Streptomycin entered the first
clinical trial at the Mayo Clinic in the winter of 1944 and soon after became the first official
anti-TB drug. It took only a few years for streptomycin-resistant TB to emerge and bring
the despair back. At the same time, the discovery and development of para-aminosalicylic
acid (PAS) opened a new avenue for TB treatment. It was soon discovered that when
PAS was co-administered streptomycin, the rate of resistance was decreased. In the
following decade, discovery and development of isonicotinic acid hydrazide (isoniazid)
(1951), pyrazinamide (1952), cycloserine (1952), ethionamide (1956), rifampin (1957)
and ethambutol (1962) paved the way for effective TB combination therapy. Currently,
there are 10 drugs approved by the Food and Drug Administration (FDA) for the treatment
of TB.
Effective TB treatment requires accurate diagnosis in the early stage as well as drug
resistance screening and directly observed therapy. Depending on the resistance profile,
current anti-TB regimen includes first-line and second-line drugs. WHO recommends a
further classification of anti-TB drugs into five groups based on safety, efficacy,
administration and drug class (Table 1.1).
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Table 1.1. WHO classification of anti-TB agents

Groups

Drugs

Group 1: First-line oral anti-TB agents

Isoniazid, Rifampicin, Ethambutol, Pyrazinamide

Group 2: Injectable anti-TB agents

Streptomycin, Kanamycin, Amikacin, Capreomycin,
Vincomycin

Group 3: Fluoroquinolones

Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin,
Gatifloxacin

Group 4: Second-line oral anti-TB agents

Ethionamide, Prothianomide, Cycloserine, Terizidone,
Thioacetazone, para-Aminosalicylic acid

Group 5: Agents with unclear role

Clofazimine, Linezolid, Amoxicillin/Clavulanate,
Imipenem/Cilastatin, Clarithromycin, High dose isoniazid

1.6.1 Drug-susceptible TB and first-line drugs
The current recommended regimen for drug-susceptible TB includes a combination of
first-line drugs isoniazid, rifampicin, pyrazinamide, and ethambutol. The treatment
requires administration of all four drugs for the first two months (intensive phase) followed
by four months of isoniazid and rifampicin (the continuation phase). This regimen is
currently used for treatment of pulmonary and extrapulmonary TB.32
1.6.2 Drug-resistant TB and second-line drugs
Proper treatment of drug-resistant TB requires individualized regimen based on the drugsusceptibility tests. The lack of culturing facilities in the affected regions and the slow
growth rate of the mycobacteria have been challenging this goal. Currently, the choice of
drugs is based on the pattern of resistance in that geographical region and the history of
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the patient. MDR-TB is defined by resistance to at least isoniazid and rifampicin, the two
most effective first-line drugs. Treatment of MDR-TB requires the administration of a
combination of second-line drugs including para-aminosalicylic acid, streptomycin,
ethionamide, capreomycin, kanamycin, amikacin, ofloxacine, and cycloserine for 18-24
months. XDR-TB is further complicated by additional resistance to fluoroquinolones and
any of the second-line injectable drugs. Treatment options for XDR-TB are very limited
and complex. Totally drug resistant (TDR)-TB is resistant to all available TB drugs and is
currently untreatable.32–34
1.6.3 TB vaccine
Vaccination is the most efficient and cost-effective way to control infectious diseases.
Since its introduction in 1921, the BCG vaccine has been the most widely used vaccine
in the world, received by 3 billion people. BCG is efficient in protecting children against
TB but its efficiency against adult pulmonary TB has been argued. Despite the
controversy, BCG remains the only vaccine in use for TB prevention.35 High risk of failure
due to the complex biology of the disease and low commercial value has made TB
vaccine development unappealing to industry. However, the public health benefits of
improved TB vaccines, even with partial efficacy, has renewed funders interest in TB
vaccine development. Current TB vaccines in development are categorized into three
main groups. Whole cell-derived vaccines including VaccaeTM, VPM1002, MTBVAC,
DAR-901 and RUTI induce both humoral and cellular immune responses to a range of
proteins, lipids and antigens. Viral vectored vaccines such as Ad5Ag85A, ChAdOx185A
and TB/FLU-04L are viral vectors expressing antigen 85A (Ag85A). Ag58A is a mycolyl
transferase enzyme involved in cell wall synthesis. Adjuvanted protein subunit vaccines
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are the third group of TB vaccines developed as boosters of BCG vaccine to prevent de
novo infection and reactivation in those already infected. Examples of this group are
M72+AS01E, H4+IC31, H1+IC31 and H56+IC31.36,37 There is a hope that the current
pipeline will lead to the development of a global vaccine that would lower the individual
and societal burden of TB and in particular antibiotic-resistant TB.

1.7

Antibiotic Resistance in Mtb

Antimicrobial resistance (AMR), driven by the abuse and misuse of antibiotics, has
become a serious challenge facing global health. This threat is usually caused by bacteria
capable of extensive horizontal gene transfer (HGT), frequent acquisition of new genes,
and to some extent by chromosomal mutations. However, Mtb is unique in this regard.
With strict clonal reproduction, very limited genetic diversity, low mutation rate and lack
of HGT it is theoretically unlikely for Mtb to pose a resistance threat. Yet, MDR and XDR
strains have emerged a few decades ago and continue to circulate worldwide. Based on
the molecular mechanism, drug resistance can be categorized into acquired and intrinsic
resistance, with the latter being the dominant strategy in Mtb.38,39
1.7.1 Acquired resistance
Acquired resistance in Mtb is caused by prolonged pressure of drug exposure due to the
lengthy regimens and has led to the selective evolution of resistant phenotypes with
survival advantages over their susceptible counterparts, an epitome of Darwin’s theory of
evolution.38 Examples of these mutations that confer resistance to first- and second-line
TB drugs are listed in Table 1.2.
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Table 1.2. List of mutations that confer resistance to anti-TB agents
Drug
Isoniazid

Mode of action
Inhibition of mycolic acids
biosynthesis and other
metabolic processes

Mutated gene
katG

Gene function
Catalase-peroxidase

inhA

Enoyl ACP reductase

ndh

NADH dehydrogenase II

ahpC

Alkyl hydroperoxidase

Rifampicin

Inhibition of transcription

rpoB

bsubunit of RNA
polymerase

Pyrazinamide

Inhibition of trans-translation

pncA

Pyrazinamidase

rspA

S1 ribosomal protein

Inhibition of arabinogalactan
synthesis

embCAB

Arabinosyltransferases

embR

embCAB transcription
regulator

Inhibition of translation

rpsL

S12 ribosomal protein

rrs

16S rRNA

gidB

16S rRNA
methyltransferases

rrs

16S rRNA

eis

Acetyltransferase

ethA

Flavin monooxygenase

inhA

Enoyl ACP reductase

ethR

ethA transcription
repressor

Ethambutol

Streptomycin

Amikacin/Kanamycin

Ethionamide

Inhibition of translation

Inhibition of mycolic acid
biosynthesis

ndh
mshA

NADH dehydrogenase II
Glycosyltransferase

Fluoroquinolones

Inhibition of DNA gyrase

gyrA

DNA gyrase subunit A

gyrB

DNA gyrase subunit B

1.7.2 Intrinsic resistance
The intrinsic resistance of Mtb to a number of antimicrobial compounds is usually
attributed to its impermeable mycolic-acid-rich cell wall. The ability of Mtb to hide in
pulmonary cavities and lesions, areas with limited drug penetrance, is another reason for
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its resistance to chemotherapeutic agents. Also, Mtb belongs to the order of
Actinomycetales which includes Streptomyces species, the famous producers of a wide
range of antibiotics. Members of this order have developed different defense mechanisms
that protect them against their own toxins. An example is the reduced susceptibility to
macrolides, chloramphenicol, tetracycline, and aminoglycosides caused by the activity of
whiB7 regulon, common in all Actinomycetales. In Mtb, this regulon expresses genes
involved in drug efflux (tap), a putative macrolide exporter (Rv1473), the ribosomal
methyltransferase erm and the aminoglycoside acetyltransferase eis.34,38–40
Considering the increasing rate of MDR- and XDR-TB, there is an urgent need for
improving our understanding of resistance mechanisms and designing new drugs to
defeat this surprisingly adaptable foe. Although the advent of fast and affordable
sequencing technologies, increasing sources of information, and shared databases are
taking us closer to this goal, there are still many challenges and questions that need to
be addressed.

1.8

The Challenge of TB Drug Discovery

Despite half a century of anti-TB chemotherapy, TB remains a global emergency. Poor
adherence due to lengthy treatment, interrupted access to drug supplies in resource-poor
countries along with other inherent problems have made the outcomes of current TB
therapy far from ideal. The situation is further hampered by the emergence of MDR- and
XDR-TB. The regimen required for treatment of drug-resistant TB is even longer and
associated with severe side effects such as nephrotoxicity, ototoxicity, hepatotoxicity,
dysglycaemia and even psychiatric disorders.41,42 Frequent co-infection of TB in HIV
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positive patients and incompatibility of TB drugs with anti-retrovirals have made the matter
worse. For instance, rifampicin, one of the most effective TB drugs, is shown to increase
the expression of hepatic cytochrome (CYP) P450 which leads to increased metabolism
and subtherapeutic concentrations of HIV protease inhibitors.43
These Issues highlight the necessity of developing new regimens with shorter
treatment duration, compatibility with anti-retrovirals, improved safety and tolerability
profile, and activity against MDR- and XDR-TB.
1.8.1 Current Pipeline
The last decade has witnessed a renaissance of activity in TB drug discovery and
development which has led to several new compounds in different stages of preclinical
and clinical trials (Figure 1.2). This has been achieved by repurposing and redosing of
old drugs as well as developing new compounds.33

Figure 1.2. TB drug development pipeline
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Repurposed compounds. Gatifloxacin and moxifloxacin are two fluoroquinolones
currently in Phase III clinical trials to replace ethambutol and reduce treatment duration
to four months.44 Rifapentine, a rifamycin with a long half-life of 13-14 hours, is in Phase
III clinical trial to replace rifampicin.33 Clofazimine, a leprosy drug, is another example of
a repurposed compound for treatment of MDR-TB.45 Oxazolidinones are also under
investigation as protein synthesis inhibitors in Mtb. Linezolid and sutezolid are two
oxazolidinone in Phase III clinical trials.33 The combination of meropenem and clavulanate
is another innovative strategy for taking advantage of existing antimicrobials. Mtb is
naturally resistant to b-lactams owing to its efficient b-lactamase BlaC. Clavulanate, a blactamase inhibitor, sensitizes Mtb to meropenem. This combination has shown to be
successful in treating MDR- and XDR-TB.45
Novel compounds. The most known example of this group is bedaquiline, a
diarylquinoline that inhibits the c subunit of ATP synthase leading to the decrease of the
intracellular ATP levels. An outstanding feature of bedaquiline is its activity against both
active and latent TB due to the necessity of ATP synthesis in both replicating and dormant
Mtb cells. Bedaquiline is currently in Phase III clinical trials.44 PA-824 and OPC67683
(also known as delamanid) are two nitroimidazoles in Phase II and Phase III clinical trials,
respectively. Both compounds are prodrugs activated intracellularly by F420-deazaflavindependent nitroreductase (Ddn) present in Mtb. Their cytotoxicity effect is due to the
generation of reactive nitrogen species including nitric oxide (NO).33,44 SQ109 is a novel
1,2-ethylenediamine-based analogue targeting MmpL3, an essential protein membrane
belonging to the resistance, nodulation, and division (RND) family. MmpL3 is the
transporter of trehalose monomycolate and its inhibition leads to the disruption of mycolic
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acid biosynthesis. SQ109 is in Phase II clinical trial to replace ethambutol, an inhibitor of
arabinogalactan synthesis.42 Benzothiazinones are very well studied inhibitors of Mtb with
low nanomolar bactericidal activity. BTZ043, a member of this class, targets the essential
enzyme decaprenylphosphoryl-beta-D-ribose 2’-epimerase (DprE1). DprE1 is essential
for the synthesis of arabinogalactan and lipoarabinomannan. BTZ043 acts as a suicidal
substrate for DprE1 to form a nitroso-species that covalently binds to a cysteine residue
in the active site and inactivates the enzyme. This compound is currently at toxicity
assessment stage of preclinical development.46
1.9

Folate Biosynthetic Pathway

To address the current and future challenges associated with TB therapy and achieve
global control of this disease, there is a pressing need for new drugs. In developing new
drugs to combat TB, novel targets are required to tackle the worsening drug-resistance
problem that compromises current TB therapy. Many pathways including cell wall
metabolism, cellular respiration, and protein synthesis have offered promising targets for
TB drug development. In this project, we have focused on the folate biosynthetic pathway
as a target to develop novel anti-TB agents. In most species, including human, the folate
pathway is essential in the synthesis of reduced folates, the one-carbon donors needed
for the production of dTMP, purine nucleotides, methionine and histidine.47 However,
humans do not have the ability to synthesize the folates de novo and instead use a
membrane-bound reduced folate carrier to bring dietary folic acid into the cell, where it is
then reduced to the final products.
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1.9.1 Bacterial Folate Pathway
In bacteria and protozoa, the pathway begins by the synthesis of para-aminobenzoic acid
(PABA) and 7,8-dihydropterin pyrophosphate (DHPPP) (Figure 1.3). PABA is
synthesized from chorismate in two steps: first, aminodeoxychorismate (ADC) is made
from chorismate and glutamine, and second, ADC is converted to PABA. DHPPP is
produced from guanosine triphosphate (GTP) via a multistep process shown in figure 2.1.
Dihydropteroate synthase (DHPS) catalyzes the condensation of DHPPP and PABA to
generate 7,8-dihydropteroate (DHP), followed by the conversion of DHP to 7,8dihydrofolate (DHF) by the action of dihydrofolate synthase (DHFS).48,49
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Figure 1.3. Bacterial folate biosynthesis and related pathways
ADC: aminodeoxy chorismate, pABA: para-aminobenzoic acid, DHPPP: 7,8-dihydropterin pyrophosphate, HMDHP:
6-hydroxymethyl-7,8-dihydropterin, DHNP: 7,8-dihydroneopterine, DHNP-PPPi: 7,8-dihydroneopterine triphosphate,
DHP: 7,8-dihydropteroate, DHF: 7,8-dihydrofolate, THF: 5,6,7,8-tetrahydrofolate, DHFR: dihydrofolate reductase,
5

10

5

SHMT: serine hydroxymethyltransferase, mTHF: N ,N -methyleneTHF, 5-mTHF: N -methylTHF, TS: thymidylate
synthase, FDTS: flavin-dependent thymidylate synthase, MS: methionine synthase, SAM: S-adenosyl methionine,
SAH: S-adenosyl homocysteine

Dihydrofolate reductase, a key enzyme in the pathway, catalyzes the reduction of DHF
to THF using NADPH as an electron donor. Serine hydroxymethyltransferase (SHMT)
then transfers a carbon from serine to THF to generate N5, N10-methylene THF (mTHF).
mTHF is a key one-carbon donor for the synthesis of deoxythymidine monophosphate
(dTMP) in a reaction catalyzed by thymidylate synthase.50 mTHF is also converted to N5methyl THF which provides the methyl group for the synthesis of methionine and Sadenosylmethionine (SAM) (Figure 1.3).51
1.9.2 Folate Pathway in Mycobacteria
Despite general similarities, there are a few unique features of the mycobacterial folate
pathway that needs to be considered when designing folate inhibitors. Understanding
these differences is necessary for investigating the mechanism of action of, and
resistance to the current and future anti-tubercular agents.
1.9.3 MtbRv2671, an alternative DHFR
Rv2671 is an enzyme that has been recently shown to be involved in the Mtb folate
pathway.52 Currently, Mtb RV2671 is annotated as 5-amino-6-ribitylamino-2,4(1H,3H)pyrimidinedione 5’-phosphate (AROPP) reductase (RibD) in the riboflavin biosynthetic
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pathway. Strains of Mtb with a mutation in 5’ untranslated region of Rv2671, which
resulted in its overexpression, were found to be resistant to DHFR inhibitors and PAS.
Following these findings, it was shown that Rv2671 is a DHFR, capable of catalyzing the
reduction of DHF to THF.53–55 This enzyme and its role in drug resistance in Mtb will be
further discussed in chapter 4.
1.9.4 Flavin-Dependent Thymidylate Synthase
Until recently, thymidylate synthase (TS, encoded by the thyA gene) was thought to be
the only enzyme responsible for dTMP synthesis. TS catalyzes the conversion of dUMP
to dTMP by using mTHF as both a carbon source and a reducing agent. The byproduct
of this reaction, DHF, is reduced to THF and sequentially mTHF by the action of DHFR
and SHMT, respectively. In the last decade, it has been discovered that Mtb and a few
other microorganisms have an additional route of dTMP synthesis via flavin-dependent
thymidylate synthase (FDTS, encoded by thyX).50,56,57 This enzyme converts dUMP to
dTMP using mTHF as the carbon source, NADPH as the reductant, and FAD as a relay
system for both a hydride and a methylene moiety. It has been also found that FDTS
overexpression is associated with PAS-resistance in clinical Mtb isolates.50 The absence
of this enzyme in human and the importance of dTMP synthesis for cell function and
survival has made FDTS a new antibiotic target. This enzyme and its function will be
further discussed in chapter 5.55
The potential of the folate pathway as a target for antibacterials development has been
acknowledged for many years and validated by the clinical use of several drugs.48
Druggable targets along this pathway and differences between human and microbial
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folate biosynthesis offer opportunities for development of novel and selective
antimicrobial agents.

1.10 Antifolates
Antifolates, compounds that interrupt the production of reduced folates, are among the
oldest antimetabolites and antimicrobial agents (Figure 1.4). The history of antifolates
starts with the discovery of Prontosil’s antimicrobial effect in the early 1930s when
scientists at Bayer found that a red dye clears the infection in laboratory animals although
it was not able to do the same in vitro. Later, it was discovered that Prontosil is a prodrug
and is metabolized to the active agent, sulfanilamide, which was found to be a mimic of
PABA and a potent inhibitor of DHPS. Followed by the discovery of sulfamethoxazole
(SMX), another DHPS inhibitor, sulfonamides became the first systemic antimicrobial
drugs and opened a new era in medicine.58,59,60
The development of antifolates derived from efforts to treat leukemia. In the late
1930s, the discovery and identification of folic acid as a growth factor led to the hypothesis
that an antagonist of folic acid might have clinical utility as a treatment for leukemia.
Sydney Farber and colleagues synthesized aminopterin by substituting an amine for the
hydroxyl group at C4 of the pteridine ring of folic acid. This compound was shown to
produce temporary remission in children with acute lymphocytic leukemia (ALL) and
suggested that this and other malignancies would be conquerable with chemotherapeutic
agents. Aminopterin was later replaced by methotrexate (MTX), a 4-amino-10-methyl
substituted analog which is a potent inhibitor of human DHFR. MTX is currently used as
a chemotherapeutic agent for the treatment of a number of cancers including head, neck,
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leukemia, lymphoma, lung, osteosarcoma, and bladder. MTX is also used as an
immunosuppressant for the treatment of autoimmune diseases such as rheumatoid
arthritis, psoriasis, lupus, and sarcoidosis.48,61

Figure 1.4. Clinically used antifolates

The success of antifolates in the treatment of tumors also led to the idea of using this
class of drugs in the treatment of other rapidly dividing cells such as bacteria and
parasites. The approach to chemotherapy via rational design and screening for
antimetabolites was explored at Wellcome by George Hitchings and Gertrude Elion in the
1940s. They recognized that folate utilization was competitively inhibited by nearly all 2,
4-diaminopyrimidines. Later, it was shown that these compounds block the reduction of
DHF to THF by inhibiting DHFR. The design and screening of analogs led to the
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development of trimethoprim (TMP), a well-tolerated DHFR inhibitor with excellent
antibacterial potency. Additionally, it was shown that TMP and SMX acted synergistically
and their combination (Bactrim) became a widely used therapy to treat bacterial infections
caused by Gram-positive and Gram-negative bacteria.62
Other antifolates in clinical use include pyrimethamine, a DHFR inhibitor used in the
treatment of malaria, 5-flurouracil and Raltitrexed, both TS inhibitors used for treating
colorectal cancers, and Pemetrexed, a dual inhibitor of DHFR and TS used for the
treatment of pleural mesothelioma and non-small cell lung cancers.63–65
1.11 Antifolates in TB therapy
Although antifolates are widely used for treatment of bacterial infections, malaria,
autoimmune disorders and neoplastic diseases, they are an underutilized drug class in
TB therapy. Despite evidence that some of these molecules can target Mtb in vitro, PAS
remains the only antifolate in the TB drug regimen.
1.11.1 PAS Mechanism of Action
Due to its structural similarities with PABA, for many years it was thought PAS works
against Mtb cells as a result of DHPS inhibition. In 1999, Nopponpunth et al. showed that
PAS is a poor inhibitor of MtbDHPS (Ki= 1176 nM).66 Comparison of PAS to other potent
DHPS inhibitors such as SMX and dapsone (with Ki values of 28 and 13 nM, respectively)
suggested that PAS antitubercular effect is not due to DHPS inhibition. In 2013,
Chakraborty et al. found that PAS is kinetically a competent substrate for MtbDHPS (Km=
1.8 µM) and results in the accumulation of PABA and the formation of a DHF analog.49
PAS biotransformation is confirmed by extracting N-mono-methyl (active metabolite) and
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N-dimethyl PAS (inactive metabolite) from PAS-treated cells. Treatment with PAS also
resulted in a selective increase in serine, homocysteine, and dUMP levels. All together
suggest that PAS affects Mtb folate pathway downstream of DHPS. Later that year,
Zheng et al. showed that PAS growth inhibitory effects against Mtb and M. bovis BCG is
reversible by adding PABA, confirming that PAS competes with PABA for the DHPS
active site. They also found that overexpression of dfrA leads to PAS resistance
suggesting DHFR as a potential target for PAS bioactive metabolite.54 The mechanism of
action of PAS will be further discussed in chapter 5.
1.11.2 Mechanisms of Resistance to PAS
Resistance to PAS emerged shortly after its introduction into clinical use especially when
used as monotherapy. Like many other drugs, PAS-resistance can be conferred via
multiple mechanisms including changes in the target or the impact of target inhibition,
altered drug metabolism, decreased drug penetration, and efflux.67
Loss-of-function mutations in thyA are shown to confer resistance to PAS in Mtb and
M. bovis. By rapid consumption of THF, thyA activity results in an increased demand for
DHFR activity to replenish sufficient levels of THF. Loss-of-function mutations in thyA
significantly decrease the need for DHFR activity and is commonly associated with
resistance to DHFR inhibitors. Since Mtb expresses both thyA and thyX, thyA mutants
are still viable due to FDTS activity.54,68
Overexpression of dfrA and Rv2671 have also shown to be associated with PASresistance suggesting that the active metabolite of PAS has anti-DHFR activity. A
mutation 11 bp upstream of the Rv2671 promoter, which causes overexpression, was
found in PAS-resistant Mtb clinical isolates.55
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As mentioned before, PAS is a prodrug converted to its active metabolite by the action
of DHPS and DHFS. A few recent studies have found folC mutations in Mtb clinical
isolates were associated with up to 64-fold increase in their susceptibility to PAS. It was
also found that folC mutations were the most pre-dominant mutations in clinically isolated
PAS-resistant Mtb strains from Northern China. These mutations correspond to substrate
binding and nucleoside binding domains that are essential for DHFS activity.53 These
observations suggest that these mutations confer resistance by preventing the
biotransformation of PAS to its active metabolite.
Drug extrusion by the multidrug efflux pumps serves as an important mechanism of
drug resistance. The Mtb genome encodes 46 putative drug efflux systems of which 22
have been shown to confer resistance. In M. bovis, overexpression of the superfamily
drug efflux pump Tap (Rv1258c), is shown to confer resistance to PAS, gentamycin,
streptomycin, spectinomycin, tetracycline, triclosan, and vancomycin. In Mtb, Tap
expression is elevated in the presence of rifampin and ofloxacin in vitro.67
1.11.3 TMP-SMX combination therapy
The findings on PAS mechanism of action and its potential to be a prodrug for DHFR, and
the determination of the structure of Mtb DHFR, has renewed interest in utilizing
antifolates, and in particular DHFR inhibitors, as antitubercular agents.
Several studies have investigated the antimycobacterial effect of SMX, TMP and their
combination. SMX was shown to inhibit the growth of Mtb cells with a minimum inhibitory
concentration (MIC) of 8 µg/mL. TMP is a weak inhibitor of Mtb cells most likely due to its
weak DHFR inhibition (IC50= 16 µM). However, TMP/SMX combination is shown to be
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synergistic and effective against drug-susceptible and MDR strains of Mtb, suggesting
opportunities for potentiation of antifolates action in Mycobacteria.69–72
Beside the known antifolates, several studies have focused on screening new
MtbDHFR inhibitors and identified a few compounds with improved inhibitory activity
relative to TMP.73–75

1.12 Propargyl-Linked Antifolates
Innate and acquired resistance to TMP has limited its use as an effective antibiotic. Efforts
to overcome this problem have led to the development of novel antifolates with activity
against various microbial pathogens.
Propargyl-linked antifolates (PLAs), developed by Anderson and Wright using
structure-based drug design approach, are a series of compounds designed to inhibit
both TMP-sensitive and resistant DHFR enzymes.76,77 These TMP-inspired DHFR
inhibitors, possess a pyrimidine ring (ring A) linked to an aryl or heteroaryl system (ring B
and C) through a propargyl bridge (Figure 1.5).
Initial structural studies of DHFR from Cryptosporidium hominis (Ch DHFR) in complex
with TMP demonstrated a narrow hydrophobic tunnel in the binding site that was
inaccessible by TMP due to its relatively compact structure. This suggested that
compounds with extended structures are likely to gain an advantage from interactions
within this hydrophobic pocket.
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Figure 1.5. Propargyl-linked antifolates

This led to the synthesis of the first generation of PLAs that differed from TMP by a
propargylic linker, extending the trimethoxybenzene ring deeper into the hydrophobic
pocket. Addition of a chiral methyl group to the propargyl position and another methyl
group to C6 position of the diaminopyrimidine ring enhanced the hydrophobic interactions.
This initial series showed improved affinity for Ch DHFR when compared to TMP (IC50
values of 0.038 m M and 14 m M, respectively).76
To further improve the potency and selectivity of PLAs, a second generation of
compounds was synthesized by adding a second benzene ring to the trimethoxybenzene.
These biphenyl series showed an improved affinity for DHFRs from C. hominis, Candida
glabrata and Candida albicans and improved selectivity over human DHFR.78,79,80 These
compounds were also shown to be potent against Staphylococcus aureus strains that are
resistant to TMP due to F98Y mutation in their chromosomal DHFR (IC50 of 0.17 m M
comparing to 1.7 m M for TMP).81,82
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The third and current generation of PLAs features a heterocyclic system which
enhanced the MIC of these compounds against MRSA (0.02 m M) and Streptococus
pyogenes (0.012 m M) when compared to TMP (MIC of 0.14 and 0.15 m M for MRSA and
S. pyogenes respectively). At the enzyme level, this series showed improved inhibition of
SpDHFR (IC50 0.019 m M) comparing to TMP (IC50 13 m M).83–86

1.13 Closing Remarks
More than one hundred years after Robert Koch identified Mtb, TB remains the leading
cause of death from an infectious disease. The bacterium’s resilient nature and its ability
to develop resistance have challenged the ongoing efforts to control this deadly but
curable disease. There is a great need for developing new chemical scaffolds along with
the identification of new drug targets that can address existing issues and curb the
emergence of resistance.
The essential nature of the folate biosynthetic pathway has provided a rich source of
drug targets that are applicable to a wide group of therapeutic indications, all of which
share the need for antiproliferative agents. Although no classical DHFR inhibitor has been
used clinically for the treatment of TB, recent studies on the mechanism of action of PAS,
and successful TB treatment with TMP/SMX combination suggest that targeting the folate
pathway in Mtb is an effective strategy for inhibiting the growth of the organism. The
rational design of PLAs has led to the development of potent DHFR inhibitors with
excellent growth inhibitory activity against several pathogenic strains as well as clinical
isolates. Considering the importance of designing anti-TB drugs with novel scaffolds and
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targets to combat drug resistance, PLAs provide a valuable source of candidates for
screening and design of novel anti-tubercular agents
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Antimycobacterial Activity of Propargyl-Linked Antifolates
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Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and DrugResistant Mycobacterium tuberculosis. PLoS ONE 2016, 11, e0161740.
10.1371/journal.pone.0161740

Contributions: The MIC data presented in this chapter were collected by Carolyn Shoen
in BSL-3 laboratories of Syracuse VA Medical Center. The compound design and
synthesis was done by Eric Scocchera, Narendran G-Dayanan and Santosh Keshipeddy.
My contribution to the work discussed in this chapter was the experiment design,
determining physiochemical characteristics, and structure activity relationship analysis.

2.2

Introduction

Despite its great potential, the target-based approach has been unsuccessful in TB drug
discovery. Many compounds with excellent on-target activity have failed to permeate
through the mycolic acid-loaded cell wall of Mycobacteria.1 An example of this problem is
MTX which despite potent inhibition of Mtb DHFR (IC50=10-20 nM) does not show strong
antimycobacterial activity (MIC ≥ 100 m g/mL), most likely due to the lack of permeability.2
To circumvent this issue, whole cell phenotypic screening provides a powerful starting
point to identify hit compounds that inhibit the growth of live mycobacteria.
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To improve current TB drug discovery strategies, it is important to mention that almost
all anti-TB drugs are discovered by whole cell screening, the mechanism of action of
many old drugs is still unclear, no anti-TB drug was found by target-directed high
throughput screening (HTS), and several drugs are shown to be prodrugs.1,3 This raises
the question, is target-directed drug discovery a realistic approach for TB?
With this question in mind, we used whole cell screening to identify PLAs with
antimycobacterial activity. It is worth mentioning that the whole cell screening is partially
biased due to our previous knowledge about the DHFR inhibitory activity of PLAs against
various species.4–8

2.3

Growth Inhibitory Effect of PLAs against Mtb Erdman Strain

We performed a first round of screening with 23 PLAs against Mtb Erdman strain (ATCC
35801) (Table 2.1). Erdman strain was isolated from human sputum by William Feldman
in 1945 at Mayo Clinic. Due to its consistently high virulence it has been widely used as
a standard laboratory strain for virulence and immunization studies.
The screened PLAs fall into two general subsets of meta-linked and para-linked
compounds. All the compounds with weak growth inhibition (MIC values of 16-32 m g/mL)
are para-linked. No compound from this category showed promising inhibitory activity.
Potent compounds with MIC values of 1-4 m g/mL were meta-linked, charged compounds
(UCP1106 and UCP1133), benzodioxalane compounds (UCP1098 and UCP1102) and
pyridine compounds (UCP1063 and UCP1071).
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Table 2.1 Antimycobacterial activity of PLAs against Mtb Erdman strain (1 round of screening
Compound

MIC
(m g/mL)

Structure

NH2

Compound

O

O
NH2

N

UCP1018

H 2N

MIC
(m g/mL)

Structure

16

N

UCP1104

N
H 2N

4

N

O
N
H

O

O

O

NH2

UCP1039

N
H 2N

NH2

O
O

N

32

UCP1106

N
H 2N

N

O

NH2

UCP1055

N

N
H 2N

4

N

32

N

NH2

UCP1109

N

O

UCP1063

H 2N

N

O
NH2

2

N

UCP1113

N
H 2N

O

NH2

4

N
N

UCP1116

N

N
N

O

NH2

NH2

4

N
H 2N

N

UCP1122
H 2N

N

8

N
N

O

2
N

UCP1128

16

N
H 2N

N

N

N

N

O

O

NH2

UCP1088

NH2

N
H 2N

CF3

NH2

N
H 2N

N

O

NH2

UCP1084

8

N
H 2N

N

UCP1071

N
H

Cl

O
NH2

H 2N

4

N

N

UCP1066

N

O

(S)

N
H 2N

8

N

O
NH2

OH

N

16

N

UCP1132

8

N
H 2N

N

N
H

N
O

O

NH2

UCP1098

N
H 2N

NH2

O

(R)

O
N

4

UCP1133

N
H 2N

1

N
OH

N

NH2

UCP1099

NH2

O

(S)

N
H 2N

O

O
N

8

UCP1135

N
H 2N

O
N
N

N
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16

NH2

UCP1101

O

N

16

N
H 2N

N

UCP1138

N

NH2
N
H 2N

N

O

D

O

D

16

N
H 2N

N

UCP1102

NH2

N

NH2

2

N
N

Building on these relationships, a second round of screening explored additional
charged compounds (Table 2.2). In this round, all compounds with MIC values of 0.03-1
m g/mL (UCP1164, UCP1172, UCP1175, UCP1205, UCP1206 and UCP1208) contained
carboxylic acid para substitution (PLA-COOH). Moving the carboxylic acid from para to
ortho position (UCP1124), or replacing it with hydroxamic acid (UCP1207) reduced the
compounds potency. Para-linked compounds again did not show any promising inhibitory
activity (UCP1139 and UCP1170).
Although at this point it is not clear that the variations in MIC values are due to the
differences in permeability of these compounds or their potency at enzyme level, overall
the para PLA-COOH compounds are the most potent PLAs. Variation in propargylic
substitution including hydrogen, methyl, or enantiopure methyl, along with 2’ or 3’
methoxy substitution contribute to the differences in MIC values between these
compounds.
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Table 2.2. Antimycobacterial activity of PLAs against Mtb Erdman strain (2
Compound

MIC

Structure

(m g/mL)

Compound

O

NH2

16

OH
N

UCP1172

H 2N

<0.03

N

O

NH2

OMe

16

N

OMe

N

UCP1175

H 2N

0.125

N

NH2
O

NH2

Cl

4

N
H 2N

OH

O

(R)

N

NH2

UCP1142

OH

N

NH2

H 2N

(m g/mL)
OMe

(R)

O

UCP1139

MIC

N

N
H 2N

round of screening)

Structure

NH2

UCP1124

nd

N

UCP1205

H 2N

O
N

0.25

N
O

OH

OMe
NH2

UCP1163

NH2
(S)

H 2N

16

N

O

UCP1206

H 2N

UCP1164

O

OH

NH2

1

N

O

UCP1207

H 2N

2
NH
OH

NH2

O

N

32

N
H 2N

O

O

Cl

UCP1170

O

N

OH

NH2
H
N

N

UCP1208

H 2N

0.25

OH

N

(R)

N
H 2N

O
N

OMe
NH2

O

(S)

N

N

O
N

0.5

N

t-Bu

O

O

NH2

UCP1171

O

N
H 2N

O
N
Cl

2.4

OH

16

N

Inhibition of MDR and XDR Mtb Isolates

As drug resistance is increasing in Mtb strains, the number of efficacious treatment
options is decreasing. It is critical that new drug candidates retain significant activity
against drug-resistant strains. We further evaluated the most promising lead PLAs against
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five MDR strains: Mtb365, Mtb276, Mtb 352, Mtb 56 and Mtb C-31 and one XDR strain,
Mtb 5 (Table 2.3).
Table 2.3. Antimycobacterial Activity of PLAs against MDR and XDR isolates of Mtb
MIC (µg/mL)
COMPOUNDS
Mtb Erdman
Mtb 5 Mtb 365 Mtb 276 Mtb 352 Mtb 56 Mtb C-31
UCP1113

8

16

8

16

8

8

16

UCP1106

16

8

4

16

16

16

>32

UCP1102

4

8

8

4

4

8

8

UCP1098

8

8

4

8

8

8

16

UCP1084

4

4

4

4

4

4

8

UCP1071

8

16

8

16

8

8

32

UCP1066

8

16

8

16

16

8

32

UCP1172

<0.03

0.25

<0.03

ND

0.06

0.06

8

UCP1175

0.5

2

0.125

ND

0.5

0.5

8

INH

0.125

4

2

ND

1

1

4

The resistance profile of these isolates is shown in appendix B. Overall, all strains are
resistant to INH, the first line TB drug, with MIC values between 0.25-4 µg/mL. Strains
Mtb 5, Mtb 365 and Mtb 56 are also highly resistant to rifampin with MIC values of 8, 64
and 32 µg/mL, respectively. The strains are also resistant to a variety of other agents
including ethambutol, streptomycin, and moxifloxacin (Appendix A). The PLAs are active
against the majority of MDR strains, albeit at slightly decreased levels. The compounds
did not show activity against strain C-31, suggesting the possibility of antifolate resistance
in this strain. Excitingly, compounds UC1172 and UCP1175 are very active against all
other MDR strains and, the XDR strain, Mtb 5, with MIC values of 0.03-0.25 and 0.125-2
µg/mL, respectively.
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2.5

Leucovorin and Thymidine Rescue

Supplementation assays have been used as tools to understand the effects of drug
treatment and pathway inhibition in a variety of organisms. To examine the effect of folate
pathway inhibition on Mtb survival, we supplemented Mtb cultures exposed to MIC levels
of UCP1172, UCP1175 and PAS (as the control drug) with 10 µg/mL thymidine or
leucovorin. Leucovorin (folinic acid) is a 5-formyl derivative of THF that is readily
converted to other reduced folates such as mTHF and 5-methylTHF. Since folinic acid
does not require the action of DHFR for its conversion, its function is not affected by
DHFR inhibitors. In cancer therapy, leucovorin is used to rescue the normal cells from the
toxic effect of potent DHFR inhibitors such as MTX.9 Thymidine rescue is used to probe
the effect of folate pathway inhibition on cell cytotoxicity. In the cell, thymidine is converted
to dTMP by the action of thymidine kinase. Therefore, supplementing the cells with
thymidine bypasses the need for reduced folates as the source of dTMP.

Table 2.4. Thymidine and leucovorin rescue experiment
MIC (µg/mL)
Compounds
7H10 broth

7H10 with 10 µg/mL
leucovorin

7H10 with 10 µg/mL thymidine

PAS

0.25

0.25

0.25

UCP1172

0.03

0.03

0.03

UCP1175

1

1

1
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As expected, supplementing the culture with thymidine or leucovorin failed to rescue
Mtb cells (Table 2.4). Mtb lacks the annotated enzymes required to assimilate exogenous
folate species and is unlikely to be able to transport leucovorin into the cell. The failure of
thymidine rescue supports the hypothesis that Mtb does not encode the thymidine kinase
enzyme which is required for the salvage of extracellular thymidine.2,10

2.6

Dapsone and Sulfamethoxazole synergy

The combination of some antimicrobials is synergistic, where the combined inhibitory
activity is greater than sum of individual drug activities. The combination of folate
antagonists, such as TMP, with sulfa drugs has been widely used for treatment of
bacterial and protozoal infections. The synergistic effect resulting from the combination
of DHFR and DHPS inhibitors lowers the rate of resistance, the dose of each drug and
the side effects.11
To assess if PLAs combination with DHPS inhibitors is synergistic, UCP1172
combination with dapsone or sulfamethoxazole (both known DHPS inhibitors) was tested
against Mtb Erdman strain (Table 2.5). Interestingly, UCP1172 combination with dapsone
(0.1 µg/mL) or SMX (0.4 µg/mL) was strongly synergistic with MIC values far greater than
the sum of the activity of each drug (<0.008 µg/mL). When UCP1172 was combined with
a higher concentration of SMX (4 µg/mL) no growth was observed even at the lowest
tested concentration of UCP1172. The combination of TMP with SMX (4 µg/mL) was also
strongly synergistic. This was not surprising given that the combination of TMP and SMX
has been used before for treatment of MDR-TB cases (Section 1.11.3).
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Table 2.5. Antimycobacterial activity of UCP1172 and sulfa drugs
MIC (µg/mL)
Compounds

7H9

7H9 with 0.1

7H9 with 0.4 µg/mL

7H9 with 4 µg/mL

broth

µg/mL dapsone

dapsone

sulfamethoxazole

TMP

>64

>8

>8

No growth

Sulfamethoxazole

1

NA

NA

No growth

Dapsone

8

NA

NA

No growth

1172

0.125

<0.008

<0.008

No growth

The experiments are performed in triplicates.

The observed synergistic effect between UCP1172 and sulfa drugs, consistent with
data from Plasmodium and other bacteria,2,11 confirms that DHPS and DHFR inhibitors
potentiate each other’s effects in Mtb. Although the details of this mechanism are still
ambiguous, it is generally accepted that the synergy is due to sequential inhibition of
adjacent steps in the folate pathway.

2.7

Physicochemical Characteristics

To predict the proper physicochemical properties that yield penetration of a compound
through the Mtb cell wall, we analyzed several physicochemical properties of PLAs
including molecular weight, pKa, overall charge, logP, logD and polar surface area (PSA)
(Table 2.6). The compounds are listed by order of activity from potent to moderately active
to inactive. Overall, it appears that active compounds are polar compounds, possessing
logD values below 2, and PSA values near 120. However, there are a few outliers.
UCP1124, despite sharing the same physicochemical properties with the potent
compounds, has poor antibacterial activity. Compound UCP1163 is not as active as its
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enantiomer with same physicochemical properties, UCP1164. The underlying reasons for
these differences will be further discussed in chapters 4 and 5.
Interestingly, a recent published screen of 2508 compounds from the Glaxo antifolate
library identified DQn-1, a diaminoquinazoline with an appended carboxylic acid, as the
compound with the greatest activity (MIC 0.03 µg/mL).12 DQn-1 has the following
physicochemical properties: molecular weight 343.77, logD 0.81 and PSA 129.98, which
are similar to the most potent compounds evaluated in this work. DQn-1 also shares an
isoelectric point of 5.5 with our PLA-COOHs which at physiological pH will give an
equilibrium where roughly 30% of our PLA-COOHs are charge-neutral zwitterionic. We
believe the activity of our PLA-COOHs is largely due to their ability to adopt a zwitterionic
form in solution which aids in mycobacterial cell permeation.

Table 2.6. Physicochemical properties of PLAs
Compounds

MW

pKa

Charge

logP

logD

PSA

Lipinski’s
violation

UCP1175

402.45

4.06 (-COOH)

-0.66

4.21

1.66

128.43

0

UCP1172

416.48

4.06 (-COOH)

-0.66

4.5

1.95

128.43

0

UCP1164

416.48

4.08 (-COOH)

-0.66

4.5

1.95

128.43

0

UCP1102

390.18

6.15 (-N)

0.40

2.65

2.45

115.35

0

UCP1133

416.48

4 (-COOH)

-0.66

4.50

1.94

128.43

0

UCP1104

389.45

11.35 (-NH)

0.34

2.75

2.57

117.40

0

UCP1098

387.44

4.55 (-N)

0.34

3.40

3.22

110.42

0

UCP1084

376.46

6.42 (-N)

0.44

2.86

2.64

106.12

0

UCP1106

402.45

4.08 (-COOH)

-0.66

4.5

1.95

128.43

0

UCP1142

377.88

5.01 (-N)

0.35

4.38

4.20

91.96

0

UCP1071

373.46

4.32 (-N)

0.34

4.01

3.83

101.19

0
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UCP1066

374.45

0.72 (-N)

0.34

2.79

2.61

114.08

0

UCP1063

373.45

5.16 (-N)

0.35

3.62

3.44

101.19

0

UCP1171

421.89

0.68 (-N)

0.34

4.23

4.05

110.42

0

UCP1165

431.54

3.63 (-NH2)

0.34

3.79

3.61

123.55

1

UCP1163

416.48

4.08 (-COOH)

-0.66

4.50

1.95

128.43

0

UCP1139

387.21

9.27 (-NH2)

1.33

3.68

1.65

115.94

1

UCP1135

345.41

5.92 (-N)

0.37

3.35

3.15

101.19

0

UCP1128

455.48

6.46 (-N)

0.44

5.47

5.23

101.19

1

UCP1124

402.45

3.69 (-COOH)

-0.66

4.21

1.64

128.43

0

UCP1122

329.4

5.07 (-N)

0.35

3.49

3.31

91.96

0

UCP1116

405.92

6.41 (-N)

0.43

4.65

4.41

91.96

0

UCP1113

401.46

4.57 (-N)

0.34

3.29

3.11

110.42

0

UCP1109

403.48

4.28 (-N)

0.34

3.46

3.28

110.42

0

UCP1101

347.18

6.24 (-N)

0.41

1.80

1.60

109.78

0

UCP1099

387.44

4.55 (-N)

0.34

3.40

3.22

110.42

0

UCP1088

379.49

0.12 (-N), 8.91 (-N)

1.31

2.76

1.08

108.15

0

UCP1018

416.18

-

0.34

4.07

3.88

106.76

0

UCP1170

476.20

-1.03 (-O), 15.11 (-NH)

0.34

5.73

5.55

108.17

1

UCP1055

344.41

1.45 (-N)

0.34

3.74

3.56

104.85

0

UCP1039

389.45

4.58 (-N)

0.34

3.18

3.00

110.42

0

2.8

Inhibition of DHFR overexpressor strains

For initial evaluation of the mechanism of action of PLAs, we tested the antibacterial
activity of some of the compounds on two M. smegmatis strains that overexpress dfrA
under the control of two different promoters. Overexpression of a drug target often
increases drug resistance. Inspired by this phenomenon, gene overexpression has been
used as a starting point for target identification and to find the mechanism of action of
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drugs. Overexpression of a drug target is usually associated with increased MIC levels
(at least 4-fold) which indicates on-target activity.
Table 2.7. MIC values against dfrA overexpressor strains
MIC (µg/mL)
Compounds

M. smegmatis
(parent strain)
4

M. smegmatis
(Overexpressing DHFR
Strain 1)
32

M. smegmatis
(Overexpressing DHFR
Strain 2)
32

UCP1138
UCP1128

0.5

128

64

UCP1116

0.25

64

32

UCP1113

1

64

32

UCP1106

8

>32

>32

UCP1102

1

64

32

UCP1099

1

64

64

UCP1098

0.5

64

32

UCP1084

1

64

16

UCP1071

4

128

64

UCP1066

4

4

4

The experiments are performed in triplicates.

All compounds, with the exception of UCP1066, have significantly increased MIC
values of at least 32 µg/mL in both overexpressor strains, suggesting that the
antimycobacterial activity of PLAs is most likely owing to DHFR inhibition (Table 2.7).

2.9

Conclusions

A whole cell screening has identified a few PLAs with potent antimycobacterial activity
against drug-susceptible and drug-resistant Mtb isolates. These PLAs with MIC values as
good as INH, the first-line anti-TB drug, have a para carboxylic acid substitution which we
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believe to facilitate the permeability of this compounds through Mtb cell wall by adopting
a zwitterionic form.
All the efforts to discover effective antifolates against Mtb build on the fact that
antifolates are generally excellent antimicrobial agents but lack the ability to permeate the
Mtb cell wall is and thus lack antibacterial activity. We and others12,13 have attempted to
investigate whether key physicochemical properties influence the cell membrane
permeability of small molecules. We observed that a low logD (under 2) and a high polar
surface area (>120) are associated with many of our most potent compounds. Lee also
found that logD values between 2.4 and 2.9 and higher PSA were desirable for
permeability of the Mtb cell wall. Recently, an effort to find correlations between a
database of antimycobacterial compounds and physicochemical properties led to a tool
for permeability prediction, MycPermChec.13 Clearly, understanding the properties of
permeable compounds will allow modification of existing impermeable inhibitors.
An important feature of the PLAs is their potent activity against multiple drug-resistant
strains. As drug resistance is increasing, it has become critical that new agents are
effective at killing existing drug-resistant strains. The compelling activity of UCP1172 and
UCP1175 places the PLAs within a small group of compounds that are effective against
the wild-type strain, MDR, and XDR. The potency of PLA-COOH compounds against
drug-susceptible and drug-resistant Mtb isolates, along with their synergistic effect when
combined with sulfa drugs, makes them excellent candidates for future drug development
as antitubercular agents.
Finally, despite the success of phenotypic screening in identifying hit compounds,
further analysis is required to determine the target and mechanism of action. Target
58

identification and enzyme inhibition assays will aid in revealing the underlying
mechanisms for the observed differences in MIC values.
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3
3.1

Inhibition of Mtb DHFR by Propargyl-Linked Antifolates
Preface

The work presented in this chapter is taken from the following publications:
Hajian, B., Scocchera, E., Keshipeddy, S., G-Dayanandan, N., Shoen, C.,
Kruscinska, J., Reeve, S., Cynamon, M., Anderson, A. C., Wright, D. L;
Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and DrugResistant Mycobacterium tuberculosis. PLoS ONE 2016, 11, e0161740.
10.1371/journal.pone.0161740

Hajian, B., Scocchera, E., Shoen, C., Viswanathan, K., G-Dayanan, N.,
Erlandsen, H., Estrada, A., Krucinska, J., Mikušová, K., Korduláková, J.,
Cynamon, M., Wright, D. Mechanistic Profiling of Propargyl-Linked Antifolates
and Their Antimycobacterial Activity in Comparison to para-Aminosalicylic Acid.
Unpublished manuscript.

Contributions: The compounds design and synthesis was done by Eric Scocchera,
Narendran G-Dayanan and Santosh Keshipeddy. Eric Scocchera also contributed in the
experimental design and data analysis of drug-target residence time. Differential
Scanning Calorimetry was performed with the assistance of Heidi Erlandsen. My
contribution to the work discussed in this chapter was experimental design, MtbDHFR
and HuDHFR transformation, expression, purification, and characterization, performing
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3.2

Introduction

Dihydrofolate reductase (DHFR) is an enzyme that, more than half a century after its
discovery, it still draws the attention of scientists from a variety of disciplines. The search
for DHFR was preceded by the recognition of folate-dependent enzymes (pteroproteins)
in the 1950s. Four groundbreaking observations from nutritional, metabolic, and chemical
studies triggered the search for and discovery of DHFR. 1) Administration of 14C-formate
to animals resulted in labeling of C2 and C8 of purines, the methyl of thymine, the
hydroxymethyl of serine, and the methyl of methionine. 2) The B vitamin pteroylglutamic
acid (now known as folic acid) was isolated from plants, liver, and yeast and shown to be
an essential growth factor for animals. Deficiency of folic acid compromised the

14

C

labeling of C2 and C8 of purines, thereby linking the vitamin to “one-carbon metabolism”.
3) Another folate derivative, folinic acid (also known as leucovorin or citrovorum factor)
was also isolated from natural sources and shown to be the 5-formyl derivative of THF.
Because it was known that B vitamins are converted to coenzymes that have suitable
structures to carry mobile metabolic groups, a comparison of folic acid and folinic acid
suggested that the coenzyme form of the vitamin was THF and the mobile group was the
formyl moiety. Further investigation about the interconversion of serine to glycine,
identified 5, 10-methyleneTHF (mTHF) as a C1 coenzyme in the synthesis of dTMP. By
the end of 1960, it was stablished that THF is the coenzyme for C1 groups involved in
purine, serine, and thymidylate synthesis and both formyl and methylene groups can be
carried by the coenzyme. These findings set the stage to address the question of how
THF was generated from the vitamin (folic acid). Sydney Futterman fractionated a chicken
liver extract and obtained a preparation that catalyzed the reduction of both folate and
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DHF to THF using NADPH as the reducing agent. Development of a continuous
spectrophotometric assay (measuring the absorbance of NADPH at 340 nm) paved the
way for purification and identification of DHFR and ultimately the design and synthesis of
folate antagonists such as aminopterin and MTX.1,2
The reaction catalyzed by DHFR appears very simple and involves the transfer of a
hydride from NADPH to DHF. Despite the apparent simplicity, DHFR plays a critical role
in regulating the amount of THF and its derivatives. Due to its pivotal role in cell survival,
DHFR has been the target of several anticancer and antibacterial drugs.3–6 Despite the
pharmacological validation of DHFR, it has not been fully exploited in the battle against
Mtb. In this chapter, we report the activity of PLAs against MtbDHFR and the kinetic
parameters that contribute to their potency. Determination of several co-crystal structures
of MtbDHFR bound to PLAs have aided us in understanding the basics of the drug-target
interactions. We have also evaluated the selectivity of the PLAs toward human DHFR
and determined the structural features that drive selectivity.

3.3

Mtb DHFR Characterization

MtbDHFR, cloned in pET-41a(+) plasmid and expressed in E. coli BL21 cell line, was
purified over a MTX-agarose affinity column (Methods section). Analytical gel filtration
showed that the protein eluted as a monomer at ~18,000 Da. The kinetic properties of
MtbDHFR were investigated and Michaelis constants for NADPH and DHF were obtained
by varying each substrate in the presence of a fixed saturating concentration of the other
(Table 3.1). The kinetic parameters were obtained through nonlinear curve fitting to
Equation 3.1 (Michaelis-Menten equation) using GraphPad Prism 7.0.
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𝑣=

#$%& '

(Equation 3.1)

($) '

where Vmax is the maximum velocity at saturating concentration of substrate, [S] is the
substrate concentration and Km (commonly referred to as the Michaelis constant) is the
substrate concentration that yields half-maximal velocity or stated another way, Km is the
substrate concentration that saturates half of the enzyme active sites under steady state
conditions. Lower Km values indicate higher affinity of the enzyme for the substrate.

Table 3.1. Kinetic parameters of MtbDHFR and HuDHFR
Km (µM)**
Vmax (µmol/mL/min)***
Kcat
Enzyme
(1/sec)*
DHF
NADPH
DHF
NADPH
MtbDHFR

1.67

10 ± 0.9

14.6
0.6

±

0.023
0.004

±

0.019
0.001

±

HuDHFR

0.47

8 ± 0.7

12.56
0.7

±

0.012
0.002

±

0.013
0.002

±

* Turnover number, calculated as Vmax/Et, where Et is the total concentration of enzyme active site
** The substrate concentration that results in half-maximal velocity
*** The maximum velocity

MtbDHFR had a Km value of 10 µM for DHF and 14.6 µM for NADPH. These values are
slightly higher than those reported in the literature.7,8 The wide variation between values
reported from different groups indicates that these constants are highly dependent on
assay conditions. Therefore, it is necessary to determine these constants before
performing inhibition assays. The Km values reported here were used to optimize the
inhibition assay by having saturating concentrations of the competing substrate.
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3.4

Mtb DHFR inhibition

The inhibitory activity of PLAs against MtbDHFR was measured using standard
procedures that spectroscopically followed the oxidation of the cofactor, NADPH, at 340
nm. The uninhibited reaction was used as a control to determine the IC50 value, the
concentration of inhibitor that results in 50% inhibition of the reaction velocity under a
given set of assay conditions. MTX, a potent MtbDHFR inhibitor, was used as the positive
control. Initially, the calculated IC50 values were higher than expected due to the high
concentration of the enzyme in the reaction. After adjusting the enzyme concentration
and reproducing the previously reported IC50 value for MTX, a better estimation of the
PLAs inhibitory effect was obtained (Table 3.2)
Overall, the majority of the compounds are moderate inhibitors of MtbDHFR with IC50
values ranging from 100 to 500 nM and a few compounds are very potent inhibitors with
IC50 values below 100 nM (UCP1063, UCP1172, and UCP1175). Comparison of
structurally similar compounds revealed structural features that contribute to the enzyme
inhibition. For example, comparison of UCP1084 (IC50 126 nM) with UCP1102 (IC50 582
nM) highlights the value of 2’ methoxy substitution in improving the enzyme inhibition
which is also reflected in the MIC value of these two compounds (2 and 16 m g/mL,
respectively). Removing the propargylic methyl from UCP1163 (IC50 102 nM) and
UCP1164 (IC50 111 nM) decreases the affinity (UCP1106, IC50 173 nM). Replacing 2’ or
3’ methoxy with 3’,4’-dioxalane clearly results in the loss of affinity as it can be seen by
comparing the following pairs: UCP1063 (IC50 88 nM) and UCP1098 (IC50 206 nM),
UCP1084 (IC50 126 nM) and UCP1102 (IC50 326 nM), UCP1163 (IC50 102 nM) and
UCP1205 (1249 nM), and UCP1164 (IC50 111 nM) and UCP1206 (IC50 848 nM). In terms
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of C-ring substitution, potent compounds fall into two general categories of pyridine Crings and PLA-COOH compounds. Among the PLA-COOHs, the presence of propargylic
methyl group significantly improves the affinity (UCP1172 vs UCP1175). Moving the
carboxylic acid group from the para position (UCP1106, IC50 173 nM) to the meta
(UCP1133, IC50 311 nM) or the ortho position (UCP1124, IC50 400 nM) results in loss of
affinity. Comparing two sets of enantiomerically pure compounds, UCP1098 and
UCP1099, and UCP1205 and UCP1206, suggest that S-enantiomers have better affinity
for Mtb DHFR although there is not a significant difference between another set of
enantiomers, UCP1163 (IC50 102 nM) and UCP1164 (IC50 111 nM).
Although PLA-COOHs are the most potent cell growth and enzyme inhibitors (UCP1172
and UCP1175), some of the pyridine C-ring PLAs are also potent against MtbDHFR (UCP
1063, UCP 1084 and UCP1099). In addition, the range of IC50 values seems to be
narrower than the range of MIC values. Besides the possible differences in the
permeability of these two groups of compounds, these observations suggest that either
IC50 values do not truly reflect the affinity of the compounds for Mtb DHFR, or DHFR
inhibition is not the only factor contributing to MIC values (second target). The latter
suggest the possibility of a second target. Both of these scenarios are investigated in the
future chapters.
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Table 3.2. Enzyme inhibitory effect of PLAs against MtbDHFR and HuDHFR
IC50 (nM)
Compound

IC50 (nM)

Structure

Compound
MtbDHFR

NH2

HuDHFR

Structure

O

H 2N

HuDHFR

525 ± 64

625 ± 42

173 ± 15

870 ± 33

333 ± 5

215 ± 18

1797
±179

290 ± 13

114 ± 8

207 ± 9

657 ± 92

1133 ± 76

400 ± 44

10,081 ±
239

167 ± 1

168 ± 8

239 ± 4

229 ± 15

311 ± 24

1577 ± 61

249 ± 8

281 ± 34

O
NH2

N

UCP1018

MtbDHF
R

nd

N

260 ± 20

UCP1104

N
H 2N

N

O
N
H

O

O

O

NH2

UCP1039

N
H 2N

NH2

O
O

N

297 ± 38

N

495 ± 58

UCP1106

H 2N

N

N
O

NH2

UCP1055

N

N
H 2N

249 ± 3

N

180 ± 15

NH2

UCP1109

O

N
H 2N

N

OH

N

N

O

O
NH2

UCP1063

(S)

88±17.6

N
H 2N

N

144 ± 18

UCP1113

N

Cl

O

NH2

NH2

UCP1066

263 ± 4

N
H 2N

N

233 ± 8

UCP1116

N

N
H 2N

N

N

N

O

NH2

UCP1071

N
H 2N

NH2

302 ± 33

N

2204 ±226

UCP1122

N
H 2N

N

N

O

O

NH2

UCP1084

NH2

126 ± 6

N
H 2N

N

N

1452 ±193

UCP1124

N
H 2N

OH
N

O

N
N
O

O

NH2

UCP1088

H 2N

N

302 ± 52

N

395 ± 21

UCP1128

N
H 2N

N

N
H

NH2

UCP1098

N

O

O

(R)

N
H 2N

CF3

NH2

N

O
N

NH2

206 ± 6

2914 ±422

UCP1132

N
H 2N

N

N

N

O

O

NH2

UCP1099

N
H 2N

NH2

O

(S)

O
N

122 ± 13

191 ± 14

UCP1133

N
H 2N

N
OH

N

O

NH2

NH2

N

N

UCP1101
H 2N

582 ± 68

N

704 ± 23

UCP1135

N
H 2N

O
N

N
N

N
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NH2

UCP1102

N
H 2N

N

O

D

O

D

326 ± 29

323 ± 27

UCP1138

220 ± 37

290 ± 13

10±1.7

1015 ± 60

72±3

688 ± 40

1249
±146

1394±125

848 ± 74

2468±262

322 ± 38

710 ± 22

501 ± 50

1042 ± 15

19,560 ±
200

97,179 ±
500

N
N

NH2

OMe

UCP1139

530 ± 40

N
H 2N

OMe

(R)

N

NH2

N

284 ± 22

UCP1172

H 2N

N

NH2
O
NH2

Cl

174 ± 9

N
H 2N

OMe

N

NH2

UCP1142

OH

N

106 ± 5

UCP1175

H 2N

N

N
O

OH

OMe
NH2

NH2

(S)

N

UCP1163

H 2N

O

(R)

N

102 ± 3

N

O

1632 ± 95

UCP1205

H 2N

O
N

O

OH

OH

OMe
NH2

NH2

(R)

N

UCP1164

H 2N

O

(S)

N

111 ± 7

N

O

1955 ± 46

UCP1206

O

H 2N

N

O

OH

OH

NH2
Cl

UCP1170

222 ± 21

N
H 2N

H
N

N

175 ± 6

UCP1207

H 2N

O
N

t-Bu

O

NH2

UCP1171

O
N

NH2

O

N

482 ± 20

254 ± 12

UCP1208

H 2N

O
N

N

Cl

N

MTX

3.5

NH
OH

O

O

N
H 2N

O

N

NH2

O

18±1.9

TMP

OH

Structural Studies

Structure-based drug design is a powerful tool in the drug discovery process and is
necessary for the synthesis of focused compound libraries. Crystal structures are the
most common source of structural information for drug design and development. To
investigate the molecular interactions between MtbDHFR and PLAs, we crystallized the
enzyme bound to NADPH and three different COOH-PLAs, UCP1106, UCP1172, and
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UCP1175. Unfortunately, our efforts to co-crystallize MtbDHFR with pyridine compounds
were not successful.
Similar to other DHFRs, Mtb DHFR exhibits the same general fold that is dominated
by a central b-sheet with four flanking a-helices (Figure 4.1). NADPH binds to the protein
in an extended conformation with the nicotinamide ring inserted into a cleft formed by
strand bA and bF. The pyrophosphate moiety interacts with helix dipoles by binding to the
residues at the end of helices aC and aE. The pyrophosphate also forms a salt bridge
with Arg45. The adenine ring interacts with the protein through hydrophobic interactions
with Leu65 and Leu102 and stacking interactions with Arg67 on the other side. The 2’phosophate group of the adenosyl ribose moiety form five hydrogen bonds with the side

Figure 3.1. Structure of MtbDHFR (A); Interactions between NADPH and the binding site residues

chains of Ser66, Gln68, Arg44 and the main chain of Arg67. The nicotinamide ribose
interacts with the residues in loop L1 while the nicotinamide contacts residues in bA, bE,

69

bI and loop L1. The amide group of the nicotinamide forms three H-bonds with main chain
atoms of Ala7 and Ile14.
All three PLAs bind to the same binding pocket in a similar mode reported for MTX.9
The 2,4-diaminopyrimidine ring of PLAs is deeply positioned into the hydrophobic binding
pocket making two hydrogen bonds with the side chain of Aps27, and two hydrogen bonds
with the main chain of Ile5 and Ile94. The negatively charged Asp27 is highly conserved
and critical for catalysis. The hydroxyl of Tyr100 is also 3.4 Å away from the 4-amino
group (Figures 3.2, 3.3, and 3.4).

Figure 3.2. MtbDHFR (blue) bound to NADPH (grey) and UCP1106 (cyan), surface model (A) and
binding site interactions (B)

There also water-mediated interactions between the 2,4-diaminopyrimidine ring and
Trp22, His30 and Ile113 and π- π stacking interaction with Phe31. This arrangement of
hydrogen bonds around the diaminopyrimidine ring is highly conserved among the known
DHFR structures from various species.10–15

70

Figure 3.3. Mtb DHFR (blue) bound to NADPH (grey) and UCP1172 (white), surface model (A) and
binding site interactions (B)

The biaryl moiety of PLAs is in contact with Gln28, Leu50, Pro51, Ile54, and Leu57
through hydrophobic interactions. The carboxylate of PLAs forms a hydrogen bond with
the highly conserved Arg60.

Figure 3.4. Mtb DHFR (blue) bound to NADPH (grey) and UCP1175(orange), surface model (A) and
binding site interactions (B)
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The main difference between UCP1106, UCP1172 and UCP1175 is the presence of a
propargylic methyl in UCP1172 which improves the hydrophobic interactions with Thr46
and Ile94 (Figure 3.5). The difference in the IC50 of these compounds highlights the value
of the propargylic methyl in improving the affinity of the compound.

Figure 3.5. Superposition of Mtb DHFR bound to UCP1106 (cyan),
UCP1172 (grey), UCP1175 (yellow)

3.6

Hu DHFR inhibition and Selectivity

While the function of DHFR is highly conserved among different species, the differences
in the amino acid sequence allow for the design of selective inhibitors to avoid the
cytotoxic effects of folate pathway inhibition in the host cells. Sequence alignment of Mtb
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and human DHFR indicates only 29% sequence identity, suggesting conformational and
structural differences between the two enzymes (Figure 3.6).

Figure 3.6. Sequence alignment of MtbDHFR and HuDHFR. The active site residues are highlighted
in yellow.

3.6.1 Enzyme inhibition
Hu DHFR, cloned in pET-41a(+) plasmid and expressed in E. coli BL21 cell line, was
purified over MTX-agarose affinity column. Enzyme characterization was performed using
procedures described for MtbDHFR (Section4.3) and kinetic parameters were determined
(Table 3.1). The Km values for both DHF (8 µM) and NADPH (12.5 µM) are similar to
Mtb DHFR. We then measured the anti-DHFR activity of PLAs against Hu DHFR using
the NADPH oxidation assay (Table 3.2). Most compounds have very similar IC50 values
against both enzymes. This concordance in enzyme inhibition results from the overall
similarity between the structure of the enzymes and has been noted in other studies
examining DHFR inhibition in Mtb.
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3.6.2 Structural studies of Hu DHFR
The folding of Hu DHFR is very similar to previous reports for other DHFRs.9,13,14 An eightstranded b sheet consisting of seven parallel strands and a carboxy-terminal antiparallel
strand composes the core of the protein. Five a helices are packed against the b sheet
core. In addition to these helices, residues 21-26 (sequence DLPWPP) form two turns of
a polyproline-like helix.
To better understand the structural differences between MtbDHFR and HuDHFR that
affect the affinity and selectivity of the inhibitors, we co-crystallized HuDHFR with
UCP1172 (Figure 3.7). The interactions of the 2,4-diamonpyrimidine ring that anchors
UCP1172 in the active site are very similar to what was observed in the Mtb DHFR and
UCP1172 complex. The 4-amino moiety forms a hydrogen bond with the backbone
carbonyl of Ile7 (3.0 Å) and another hydrogen bond with the backbone carbonyl oxygen
of Val115 (3.3 Å). Atom N1 and the 2-amino group form two strong hydrogen bonds with
Glu30 (2.8 and 2.6 Å, respectively). Glu30 corresponds to the conserved Asp27 among
bacterial DHFRs. There are also water mediated interactions between the 2-amino group,
Val8, and Thr136, and π- π stacking interaction between the 2,4-aminopyrimidine ring
and Phe34. The 3’ methoxy group forms a weak hydrogen bond with Ser59 (3.4 Å). In
Mtb DHFR complexed with UCP1172, the oxygen of 3’ methoxy is too far from the
corresponding Ser49 to form a hydrogen bond (5.3 Å). This change in the orientation is
most likely due to the hydrogen bond between the carboxylate and Arg60 in MtbDHFR
which is missing in the Hu DHFR and UCP1172 complex. In Hu DHFR, the corresponding
Arg70 is too far from the carboxylate of UCP1172 to form a hydrogen bond (6.0 Å).
Although the carboxylate is in the vicinity of Asn64 (3.2-3.6 Å), the angle does not seem
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to favor hydrogen bonding. The lack of optimized interactions between the carboxylate
group of UCP1172 and the Hu DHFR active site residues is likely the reason for weaker
affinity of this compound for Hu DHFR compared to Mtb DHFR.

Figure 3.7. Structure of HuDHFR in complex with NADPH and UCP1172, surface model (A), and
binding site interactions (B)

3.6.3 Structural Comparison of Mtb DHFR and Hu DHFR
Mtb DHFR contains 159 amino acid residues compared with 187 for the human protein.
Superposition of these two enzymes shows that the general fold of the two is essentially
the same, even though the human enzyme is significantly larger (Figure 3.8). The major
differences in the vicinity of the active site is found in the loop L3 which is extended by
three residues in MtbDHFR compared to the human enzyme. This extension affects the
interactions of loop L3 with loop L1. The conformation of loop L1, corresponding to the
“Met 20 loop” in the E. coli enzyme, affects the accessibility of the active site, a factor to
be considered in design of selective inhibitors.
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A notable difference in the folate binding site is Gln28 in Mtb DHFR, which corresponds
to Phe31 in the human enzyme. The design of inhibitors with polar groups that take
advantage of contacts with Gln28 would potentially yield greater selectivity at the enzyme
level.

Figure 3.8. Superposition of the binding site of Mtb DHFR (blue) and Hu DHFR (red), both in
complex with UCP1172

Differences were also observed on the helix aB where two small hydrophobic residues
in Mtb DHFR, Pro25 and Ala29, correspond to two large positively charged residues,
Arg28 and Arg32 in the human enzyme, also one negatively charged residue, Glu33 in
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Mtb DHFR, is changed into a positively charged Arg36 in Hu DHFR. Design of inhibitors
with hydrophobic substituents may allow favorable interactions with these hydrophobic
residues Ala29 and Pro25 in Mtb DHFR while decreasing the affinity of the inhibitor for
Hu DHFR.

3.7

Analysis of Thermal Stability

To better evaluate the binding affinity of the compounds to MtbDHFR, we studied thermal
stabilization of Mtb HFR upon ligand binding using differential scanning calorimetry
(DSC), an analytical technique that measures the molar heat capacity and thermal
stability of a protein as a function of temperature. It has been frequently observed that
binding of a ligand to a protein yields a complex with increased thermodynamic stability
compared to the free protein. This difference in the stability leads to a change in apparent
melting temperature (Tm) of the protein which can be measured by the DSC method.
Higher Tm and thermal stability usually correlates with better IC50 values and affinity.
Mtb DHFR bound to cofactor NADPH was used as the control sample to provide a
comparison between the Tm of the uninhibited and inhibited protein. Overall, all the
inhibitors caused an increase in thermal stability and Tm of the protein (Table 3.3). Mtb
DHFR bound to UCP1172 and Mtb DHFR bound to MTX showed the largest increase in
thermal stability (81 ºC and 75.5 ºC, respectively) comparing to the control (65 ºC). The
unfolding pattern of MtbDHFR:UCP1172 complex was broadened comparing to the other
inhibitors which can be explained by the slow dissociation of this inhibitor from the target.
Binding of UCP1175 and UCP1063 also increased the thermal stability of the protein
(72.9 ºC and 71 ºC, respectively) although to a lesser extent compared to UCP1172 and
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MTX. In sum, the changes in thermal stability of Mtb DHFR upon binding of the inhibitors
correlates with the IC50 values.
Table 3.3. Thermal stability analysis of MtbDHFR bound to PLAs and MTX
Complex

E*:NADPH

E:NADPH:MTX

E:NADPH:UCP1172

E:NADPH:UCP1175

E:NADPH:UCP1063

Tm (°C)

65

76

81

73

71

* MtbDHFR enzyme

3.8

Drug-Target Residence Time

As discussed in the section 4.4, the IC50 values of PLAs do not truly reflect their
antimycobacterial activity and in some cases, the differences between IC50 values are too
small to explain the significant changes in the MIC values. Therefore, we decided to
broaden our kinetics studies to gain better understanding of the affinity of PLAs for Mtb
DHFR.
Since the introduction of receptor theory by Paul Ehrlich and John Newport Langley in
1913, the molecular basis of pharmacology has been largely described by the binding of
drugs for their specific targets. As a result, early-phase drug discovery is usually focused
on the evaluation and optimization of target affinity. Target affinity is typically measured
in cell-free assays or “closed systems”. In such a system, the drug and target
concentrations are constant, meaning that the total concentration of both molecules are
homogenous and unchanged during the time course of the experiment. This condition is
the representative of most experimental measurements of drug-target binding in vitro. In
a closed-system the only change in concentration that takes place with time is in the
concentration of free and bound species as the system approaches equilibrium. This
condition is a poor mimic of the temporal concentrations and duration of exposure that
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the compound exerts against its target in an in vivo setting. In closed systems, the extent
of compound binding to a target is commonly measured in terms of the IC50 values (halfmaximal inhibitory concentration) or by equilibrium dissociation constant (Kd) for the drugtarget binary complex.16–18
In contrast, an open system is characterized by continuous changes in the
concentration of drug available to encounter the target. Because of the changes in drug
concentration, the equilibrium measurements are no longer appropriate. On the other
hand, the dissociation rate for the binary drug-target complex is independent of any
changes in the free drug concentration. In an open in vivo system, association rate is
affected by absorption, tissue distribution, and diffusion rate and is no longer the main
determinant of complex formation, and thus pharmacological effect. The association rate
depends not only on the biomolecular association rate constant (Kon) but also on the
concentration of the drug. A small value of Kon can be compensated for by increasing the
dose of the drug. On the other hand, the dissociation rate constant (Koff) is independent
of pharmacological factors, such as absorption and distribution rates, and is also
independent of the local concentration of free drug. Koff is entirely dependent on specific
interactions between the drug and its target binding pocket. The forces that determine
drug dissociation rate are the same forces that are commonly associated with
thermodynamic

affinity;

protein

conformation,

hydrogen

bonding,

hydrophobic

interactions, van der Waals forces, etc.19,20
In open biological systems, one of the most crucial factors for sustained drug efficacy
is not the apparent affinity of the drug for its target but rather the duration of drug-target
occupancy, which is determined by the dissociation rate. The duration of drug-target
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occupancy is referred to as the drug-target residence time (tR), the period for which a
receptor is occupied by a ligand, and can be experimentally approximated by the
reciprocal of Koff. The longer the drug-target complex endures, the longer the drug’s effect,
either in vitro or in vivo.17,21,22
It is often the case that SAR studies that are guided by IC50 or Ki measurements in closed
systems lead to the optimization of the residence time, although this is usually
unrecognized. It might be argued that the need for optimization of residence time is
already fulfilled by standard measurement of IC50 or Ki, but these values alone, without
an accompanying evaluation of Koff, provide no assessment of the temporal components
of efficacy (duration of action), which could be of critical importance for correlating the
affinity of the drug for the target to its efficacy in cell-based assays.17,22,23
3.8.1 Measuring drug-target residence time
There are a variety of methods to determine the value of Koff and, from this, the residence
time for a drug-target complex. Here, we have used “jump dilution analysis” for the
purpose of determining the rate of dissociation and the reversibility of the enzyme
inhibitors. The assay is performed by incubating the enzyme with the concentration of
inhibitor that is 10-fold higher than IC50 to achieve nearly complete binding of inhibitor to
the enzyme. After sufficient time for equilibration, the enzyme inhibitor complex is then
rapidly diluted 100-fold into assay buffer containing a high concentration of the competing
substrate to effectively cause a “jump” in the equilibrium condition. After the 100-fold
dilution, the inhibitor concentration is reduced to 10-fold below the IC50, conditions under
which inhibitor rebinding is strongly disfavored and minimal residual binding should occur.
The recovery of enzymatic activity that results from the dissociation of the inhibitor can
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be followed as a function of time after dilution.24–26 In the case of slowly dissociating
compounds, the product formation over time is curvilinear and can be fit to the Equation
3.2 to yield an estimate of the overall rate constant for drug target dissociation:
𝑃 = 𝑉, 𝑡 +

#/ 0#1
2341

(1 − 𝑒 02341 9 )

(Equation 3.2)

where P is the product concentration, Vs is the velocity of the uninhibited control reaction,
V0 is the velocity of fully inhibited reaction and can be set to zero, and t is the timeframe
of the reaction. Under the condition of minimal inhibitor rebinding, the observed rate
constant, kobs, can be considered as a reasonable estimate of koff. The residence time of
the drug-target complex is defined as the reciprocal of Koff (Equation 3.3).
𝑡; =

<
23==

=

<

(Equation 3.3)
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To improve our understanding of PLA affinity for Mtb DHFR and its correlation to the
observed MIC values, we use the jump dilution method to estimate the dissociation rate
of the most potent PLAs, UCP1172 (MIC= 0.03 m g/mL, IC50= 10 nM) and UCP1175 (MIC=
0.125 µg/mL, IC50= 73 nM) and also one of the pyridine PLAs, UCP1063, with IC50 value
close to UCP1175 (88 nM) but weaker whole cell activity (MIC= 2 µg/mL). Mtb DHFR was
incubated with each compound at a concentration 10 times higher than IC50 for a few
hours. The assay mixture was then diluted 100-fold in the assay buffer containing 100 µM
DHF and 100 µM NADPH and the recovery of enzymatic activity was measured by
following NADPH absorbance at 340 nm. Data was fit to Equation 4.1 using nonlinear
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global fitting approach in GraphPad Prism 7.0 software to yield the progress curve. The
calculated kobs value was used to determine koff and the residence time (Table 3.4).
Table 3.4. Kinetic characteristics of PLAs and MTX binding to Mtb DHFR
a
Compound
MIC(m g/mL)
IC50
Ki
koff (min-1)

a

tR (min)

MTX

>100

18±1.9

1.6

0.056±0.004

17.8

UCP1172

0.03

10±1.7

0.91

0.024±0.002

40.9

UCP1175

0.125

72±3

6.55

0.072±0.003

13.7

UCP1063

2

88±17.6

8

0.096±0.015

10.3

Calculated using Cheng-Prussof equation, Ki=IC50(1+S/Km)

After dilution, enzymatic activity was recovered for all of the compounds over the assay
timeframe (Figure 3.9). The resulting progress curves for PLAs and MTX were curvilinear
(a lag phase followed by a linear phase) suggesting slowly reversible behavior. UCP1172
showed the longest residence time on MtbDHFR (~40 minutes) and as a result of that,
the enzymatic activity recovery in the presence of UCP1172 was slower than the other
compounds.
The residence time of UCP1175 and UCP1063 were close to each other (13 and 10
minutes, respectively). The residence time of MTX (17 minutes) is much less than
UCP1172, despite having similar IC50 values, again suggesting that parameters such as
IC50 might not provide an appropriate measurement of the affinity and efficacy of the
inhibitor.
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Figure 3.9. Jump dilution progress curve for PLAs and MTX

3.9

Conclusions

The critical role of DHFR in the production of reduced folates has made it a valid target
for many anticancer and antimicrobial agents. Here, we have shown that potent
antimycobacterial PLAs have strong affinity for Mtb DHFR with IC50 values below 100 nM.
Our kinetics studies have revealed that the lead PLA, UCP1172, has a slow dissociation
rate and long residence time on the target (~40 minutes). Drugs with long residence time
often exhibit pharmacological effects that are prolonged beyond the time predicted by
rapid equilibrium models.17,27 The slow dissociation of UCP1172 from its target, makes
this compound an excellent candidate for in vivo efficacy studies. We believe that the
potency of UCP1172 is due to the combination of potent enzyme inhibition, long residence
time and permeability through the Mtb cell wall. Our hypothesis about the effect of the
carboxylate moiety on improving the permeability is supported by the comparison of
83

UCP1175 and UCP1063 which despite very similar kinetic profiles (tables 2.3 and 2.4),
exhibit different antimycobacterial activity.
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4.2

Introduction

In the past few years, investigating the mechanisms of resistance to PAS in Mtb mutants
has led to the identification of a second DHFR enzyme, Rv2671, in Mtb (currently
annotated as RibD).1 A thorough molecular genetics study of clinical isolates and
spontaneous mutants of Mtb with resistance to PAS did not reveal any mutation in DHFR
associated with resistance.2 This may suggest that the fitness cost of a mutation in DHFR
is higher than other genes in Mtb. In an effort to select spontaneous Mtb mutants resistant
to DHFR inhibitors, Zheng et al. identified a Mtb mutant resistant to NITD344, a DHFR
inhibitor, with a Gly to Ala substitution located 11 bp upstream of the translational start
codon of RibD (Rv2671), causing RibD overexpression.3 Although Rv2671 is annotated
as RibD, a protein in the riboflavin biosynthetic pathway, its C-terminal reductase domain
shares strong sequence similarities with Mtb DHFR. This Mtb mutant with Rv2671
overexpression and resistance to NITD344 was cross-resistant to PAS. Three PAS
resistant clinical isolates also showed the same mutation upstream of Rv2671, suggesting
overexpression of this protein is associated with PAS resistance.4 This observation led to
the idea that Rv2671 might function as a DHFR when expressed at high levels. Zheng et
al, showed that despite the essentiality of dfrA in Mtb, this gene can successfully be
knocked out when Rv2671 was overexpressed from a multicopy plasmid.3 These results
indicated that Rv2671 when expressed at high levels, can provide sufficient one-carbon
carriers to sustain bacterial survival in the absence of dfrA.
In eubacteria, RibD is typically a bifunctional enzyme which catalyzes the second and
third reactions of the riboflavin biosynthetic pathway, which is the conversion of 2,5diamino-6-ribosylamino-4(3H)-pyrimidinone 5’-phosphate (DAROPP) to 5-amino-6-
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ribitylamino-2,4(1H,3H)-pyrimidineodione 5’-phosphate (ARIPP). RibD catalyzes the
reaction that involves the deamination of the 2-amino group of the pyrimidine ring followed
by a reduction of the ribose ring using either NADPH or NADH. It was surprising to find
that an increased expression of an enzyme involved in riboflavin biosynthesis would
confer resistance to PAS. Soon after, Cheng et al. showed that MtbRv2671 is a DHFR
that catalyzes the reduction of DHF to THF using NADPH as the cofactor.5 Their activity
assay also showed that Rv2671 is not a DAROPP reductase, suggesting that Rv2671
and other related orthologues are not involved in riboflavin biosynthesis and are most
likely annotated incorrectly.
Regardless of annotation and nomenclature, Rv2671 has DHFR activity and its
overexpression has been shown to confer resistance to DHFR inhibitors and PAS in Mtb
clinical isolates and spontaneous mutants.1,2 Therefore, we decided to characterize
Rv2671 and test the activity of PLAs against this enzyme. Evaluate the possibility of dual
inhibition of DHFR and Rv2671 by PLAs would expand our understanding of the
mechanism of action of PLAs and their antimycobacterial activity.

4.3

Enzyme Characterization

MtbRv2671, cloned in pET-28a(+) plasmid and expressed in E. coli BL21 cell line, was
purified using nickel affinity chromatography. The enzyme activity was measured by
following NADPH oxidation at 340 nm and its kinetics parameters were determined as
described in Section 3.3.
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Table 4.1. Kinetic parameters of MtbRv2671
Km (µM)**
Kcat
Enzyme
(1/sec)*
DHF
NADPH
MtbRv2671

0.69

39 ± 0.9

9.8 ± 0.6

Vmax (µmol/mL/min)***
DHF

NADPH

0.015 ± 0.002

0.021 ± 0.004

* Turnover number, calculated as Vmax/Et, where Et is the total concentration of enzyme active site
** The substrate concentration that results in half-maximal velocity
*** The maximum velocity

The Km of Rv2671 for DHF was determined to be 39 (µM) (Table 4.1), about four times
higher than the Km for DHFR. The kcat of Rv2671 is 0.69 s-1 which is almost 2.5 times less
than DHFR. Therefore, Rv2671 catalyze the DHF reduction reaction with less efficiency
than Mtb DHFR.

4.4

Enzyme Inhibition

We then screened a series of PLAs for their enzyme inhibitory effect against Rv2671. The
calculated IC50s are listed in Table 4.2. All the tested PLAs showed potent to moderate
inhibition of Rv2671 with IC50 values ranging from 180 nM to 4 µM. The most potent
compounds are the pyridine compounds, UCP1063 (IC50= 184 nM), UCP1098 (IC50= 241
nM) and UCP1099 (IC50= 260 nM). All PLA-COOHs show moderate inhibition of Rv2671.
The lack of propargylic methyl in UCP1106 and UCP1175 results in a significant decrease
in the affinity of these two compounds (IC50 values 1165 and 4245 nM, respectively). It is
interesting to see that unlike Mtb DHFR, moving the carboxylate from the para position in
UCP1106 to the meta position in UCP1133 and the ortho position in UCP1124 improves
Rv2671 inhibition (IC50 values 3330, 851 and 712 nM, respectively).
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Table 4.2. Inhibition of Mtb Rv2671 by PLAs
RV2671
Compound Structure
IC50 (nM)

Compound

RV2671

Structure

IC50 (nM)
OMe

O
NH2

UCP1063

NH2

184 ± 12

N
H 2N

N

UCP1164

(R)

N

(S)

H 2N

510 ± 18

N

N

O

NH2

UCP1098

H 2N

NH2

O

(R)

N

OH

OMe

(R)

N

241 ± 9

O
N

UCP1172

H 2N

384 ± 15

N

N
O

OH

NH2

NH2

UCP1099

N
H 2N

OMe

N

O

(S)

260 ± 24

O
N

UCP1175

H 2N

4245 ± 230

N

N

O

NH2

OH

O

(R)

N

3330 ± 250

UCP1106

UCP1205

H 2N

O
N

O

NH2

O
NH2

UCP1124

O

(S)

OH
N

712 ± 35

UCP1206

H 2N

O
N

OH

NH2

O
NH2

O

N

N
H 2N

339 ± 22

O
O

UCP1133

OH

N

N
H 2N

636 ± 45

851 ±30

N

UCP1207

H 2N

O
N

308 ± 15

OH

O

O

NH
OH

OMe
NH2

UCP1163

NH2
(S)

H 2N

O

N

N

1165 ± 120

N

UCP1208

H 2N

O
N

420 ± 20

N
O

TMP

O

OH

OH

93,500 ±
1500

Overall, it is likely that dual inhibition of DHFR and Rv2671 contributes too good in vitro
growth inhibition. However, while dual inhibition is certainly desirable, it is not the only
factor for in vitro potency, as we can see in pyridine compounds (UCP1063, UCP1099
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and UCP1098), which despite potent dual inhibition, do not show promising MIC values.
On the other hand, most of PLA-COOHs exhibit improved antibacterial activity even with
moderate dual inhibition, suggesting the presence of carboxylate group in PLA-COOHs
facilitates the permeability and leads to better growth inhibition.

4.5

Structural Studies

To investigate the molecular interactions between MtvRv2671 and PLAs, we crystallized
this enzyme in complex with NADPH and UCP1063.
The X-ray crystal structure of MtbRv2671 was determined to 2.4 Å resolution. The crystal
belonged to the space group C2221, with one molecule in the asymmetric unit. The
structure of Rv2671 is composed of eight parallel b-strands and one anti-parallel b-strand.
This b-sheet is surrounded by seven a-helices and one 310-helix (h1). The NADPH binds
at the C-terminal edge of the central b-sheet (b2, b3, and b6) and the pyrophosphate
group locates between the a3 and a6 adjacent to the substrate binding cleft formed by
a2, a3, b2, and b3. The conformation of NADPH and its binding site is very similar to
other DHFR structures (Figure 4.1).6–8
As previously reported,5 a weak density for the nicotinamide ribose moiety of NADPH and
residues 90-95 was observed. This disorder is probably due to the lack of stabilized
interactions in these regions explaining the high Km for DHF and NADPH.
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Figure 4.1. Structure of Mtb Rv2671 bound to NADPH (grey)

The 2,4-diaminopyrimidine of UCP1063 ring makes direct hydrogen bonds with Asn44,
Asp67 (corresponding to Asp27 in Mtb DHFR) and Glu193. In addition, there is a watermediated interaction with Thr214 and a p-p stacking with Phe71 (corresponding to
Phe31 in Mtb DHFR). The nitrogen atom of the pyridine ring of UCP1063 is too far from
Asn72 and Arg68 to form a direct hydrogen bond (5.2 Å and 4 Å, respectively).
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Figure 4.2. Mtb Rv2671 (orange) bound to NADPH (grey) and UCP1063 (blue), surface model (A)
and binding site interactions (B)

In all bacterial DHFR structures, a conserved arginine residue forms hydrogen bonds
with the a-carboxyl group of the DHF glutamate tail. As mentioned in section 4.5, in Mtb,
Arg60 corresponds to the conserved arginine in DHFRs. Superposition of Rv2671 and
Mtb DHFR structures shows that Arg97 in Mtb Rv2671 corresponds to the conserved
arginine. However, Arg97 points in the opposite direction of the folate binding site and
UCP1063. It is unlikely that this Arg97 can fulfill the role of stabilizing a-carboxyl group of
DHFR or be able to form a strong interaction with current PLAs. The position of Arg97 is
likely another reason for the high Km of Rv2671 for DHF.
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Figure 4.3. Superposition of Mtb DHFR bound to UCP1172 (blue) and MtbRv2671 bound to
UCP1063 (orange)

4.6

Conclusions

Rv2671 is a second DHFR found in Mtb and its overexpression is associated with
resistance to PAS and DHFR inhibitors.1–3 Here, we have shown that lead PLAs are dual
inhibitors of Mtb DHFR and Rv2671. We believe the potent antimycobacterial activity of
PLAs is partially due to their dual inhibitory activity against DHFR and Rv2671 and total
blockage of THF formation. The structure of Rv2671 in complex with NADPH and
UCP1063 provided additional details of the drug-target interactions and elucidated key
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structural features of both the inhibitor and the target. These findings will aid in the design
and optimization of novel inhibitors of the folate pathway in drug-susceptible and drugresistant Mtb.
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assay, preparation of cDNA library for whole genome sequencing, assembly and
annotation, data analysis, and writing the manuscripts.

5.2

Introduction

As mentioned earlier in chapter 1, PAS is a second-line anti-TB drug used for the
treatment of drug resistant TB. Although PAS has been widely used clinically, its precise
mechanism of action is still unclear. Because of its structural similarities to PABA, it was
speculated that like sulfonamides, other PABA structural analogs, PAS is also a DHPS
inhibitor. Recently, it has been shown that PAS is a competing substrate for DHPS with
a Km value of 1.8 µM.1 By extracting PAS-derived pteroate and folate analogs from PAStreated cells, Chakraborty et al. (2013) suggested that PAS acts as an alternative
substrate for folate metabolism in Mtb and is metabolized to folate analogs. Later, Zheng
et al. (2013) proposed a mechanism where PAS is misincorporated into the folate
pathway by competing with PABA in the reaction catalyzed by DHPS, the product of which
is further processed by DHFS to generate a hydroxyl analog of DHF (Figure 5.1).2 They
showed that dfrA overexpression leads to PAS resistance in Mtb cells and that the DHFR
enzyme was inhibited by PAS-treated mycobacterial cell lysate, suggesting PAS is a
prodrug for DHFR.
Inspired by these findings, we synthesized the PAS metabolite (PAS-M) to evaluate its
activity against MtbDHFR in comparison with lead PLAs. Understanding the molecular
mechanism of action and resistance of current drugs such as PAS will provide new
perspectives and approaches for design of novel antifolates against Mtb.
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Figure 5.1. Misincorporation of PAS into the folate pathway

5.3

Inhibition of DHFR by PAS-M

To our surprise, PAS-M showed very poor inhibition of Mtb DHFR with IC50 value of 10
µM. To obtain a better profile of PAS-M inhibitory activity against Mtb DHFR, we also
evaluated the dissociation rate of PAS-M and its residence time on the enzyme (Table
5.1). In correlation with the inhibition value, PAS-M showed very fast dissociation and a
residence time of 1.5 minutes. Differential scanning calorimetry analysis showed a small
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shift (3 °C) in the melting temperature of Mtb DHFR in the presence of saturating
concentration of PAS-M (Table 5.1).
Table 5.1. Kinetic parameters of PAS-M for Mtb DHFR and Rv2671
MtbDHFR
Compound

PAS-M

-1

MtbRv2671

IC50 (m M)

koff (min )

tR (min)

Tm (°C)*

IC50 (m M)

10 ± 2.1

0.643±0.125

1.5

68

100 ± 9.8

* Tm of the control (Mtb DHFR+NADPH) was determined to be 65 °C.

These results suggest that PAS-M is a weak inhibitor of Mtb DHFR especially when it
is compared to a potent inhibitor such as UCP1172 with an IC50 value of 10 nM and a
residence time of 40 minutes.
To further investigate the interactions of PAS-M with Mtb DHFR, we co-crystallized the
enzyme in complex with NADPH and PAS-M. The co-crystal structure gave insight into
the binding mode of this compound and the reason for its poor activity (Figure 5.2).
Comparing to MTX, the pteridine ring of PAS-M is in an inverse orientation with N1 and
N8 too far from any residue to make direct or water mediated hydrogen bonds. The N1
and 2-amino group of pteridine ring are still able to form two hydrogen bonds with Asp27.
The carbonyl group and N5 make water-mediated interactions with Trp22, His30, and
Thr113. The glutamate motif forms a salt bridge with Arg60 and a hydrogen bond with
Arg32. A large water network was also observed between the hydroxyl group and the
residues of the binding pocket. Despite these interactions, the inability of the
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Figure 5.2. Mtb DHFR (blue) in complex with NADPH (grey) and PAS-M (brown)

pteridine ring to interact with highly conserved Ile5, Ile94 and Tyr100 is likely the main
reason for the weak affinity of this compound for Mtb DHFR. Flipping of the pteridine ring
has been also observed in co-crystal structure of Hu DHFR bound to folate which is likely
responsible for the difference between the affinity of folate and MTX for Hu DHFR.3
PAS is a potent drug with an MIC of 0.03 µg/mL but its competition with PABA, and PASM poor DHFR inhibition is unlikely to explain its antimycobacterial activity. To shed light
on this question, we evaluated the possibility of PAS-M to target multiple enzymes in the
folate pathway.
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5.4

Inhibition of Rv 2671 by PAS-M

As discussed in chapter 5, Rv2671 overexpression is associated with resistance to PAS
in spontaneous mutants and clinical isolates of Mtb. It has been also suggested that
Rv2671 can bind and reduce a broad spectrum of dihydropteridine containing analogues.4
Although a high Km value of Rv2671 for DHF suggests that it is unlikely for its analog,
PAS-M, to bind to this enzyme, the ability of Rv2671 to reduce DHF encouraged us to
test the inhibitory effect of PAS-M on Rv2671 with the hope to find an explanation for PAS
cytotoxicity. As expected, PAS-M did not exhibit any promising inhibitory activity against
Rv2671 (IC50 value of 100 µM, table 6.1)

5.5

Inhibition of FDTS by PAS-M

Actively dividing cells require large quantities of deoxyribonucleoside triphosphates
(dNTPs), essential building blocks of DNA. The biosynthesis of dNTPs begins with the
reduction of ribonucleoside diphosphates (rNDPs) to deoxyribonucleoside diphosphates
(dNDPs) by the action of ribonucleotide reductase (RNR). The conversion of dNDPs to
dNTPs is catalyzed by nucleoside diphosphate kinase enzyme (NDPK). While dATP,
dCTP and dGTP can be produced directly by the action RNR and NDPK, dTTP synthesis
takes a convoluted pathway to exclude uracil from DNA (Figure 5.3).5 This additional
route involves the methylation of dUMP to dTMP by the action of thymidylate synthase
(TS). In human cells and almost 70% of microbial species, TS (encoded by thyA),
catalyzes the reductive methylation of dUMP to dTMP using mTHF as a donor of onecarbon units and as reductant. The resulting DHF is rapidly reduced to THF by DHFR.
Therefore, thyA and folA are functionally coupled in thyA-containing organisms.
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Figure 5.3. De novo synthesis of dNTPs

However, in approximately 30% of microbial species (based on complete genome
sequence) de novo synthesis of dTMP relies on flavin-dependent thymidylate synthase
(FDTS, encoded by thyX) that is evolutionarily unrelated to canonical TS.6–8 FDTS is an
NADPH oxidase that uses FAD to mediate hydride transfer to catalyze the formation of
thymidylate. The byproduct of this methylation reaction is THF, not DHF. This difference
in the reductive mechanism of TS and FDTS explains why all thyA-containing bacteria
have folA, while this gene is often absent from thyX-containing organisms. Approximately
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5% of microbial species including Mycobacterium tuberculosis express all three folA, thyA
and thyX. To date, why both thyA, and thyX genes are maintained in such organisms is
poorly understood.
Studies have shown that thyX is essential for Mtb growth and survival and its
overexpression is associated with PAS-resistance in clinical isolates.9–11 Intrigued by the
weak inhibition of Mtb DHFR and Mtb Rv2671 by PAS-M and in search of its mechanism
of action, we decided to test the inhibitory effect of PAS-M on Mtb FDTS. It has been
previously reported that high concentrations of mTHF, the FDTS substrate, shuts down
the NADPH oxidation most likely due to overlapping binding sites.12–15 Our previous
experiments also showed that folic acid, DHF, and leucovorin have the same regulatory
effect on the NADPH oxidation activity of FDTS, suggesting that this enzyme can bind to
a broad spectrum of folate analogs. Considering the structural similarities of PAS-M with
folate derivatives, the ability of this compound to bind to FDTS and interrupt NADPH
oxidation is not unlikely.
FDTS was cloned in pET-24d(+), expressed in E. coli BL21 cell line and purified by
nickel affinity chromatography. Gel filtration analysis showed that Mtb thyX behaves as a
tetramer with total molecular weight of ~119 KDa. Purified FDTS has a characteristic
yellow color because it is isolated with the cofactor FAD bound to it. To test the potential
of PAS-M as a FDTS inhibitor, we performed DSC experiment to detect binding of PASM to FDTS and its effect on the stability of protein. Because it has been shown that the
presence of dUMP and FAD improves the binding of NADPH and mTHF,12,15,16, we used
a mixture of enzyme, dUMP and FAD as the control sample. DSC analysis showed the
Tm of 66.6 °C for the control sample and 71.9 °C for the control incubated with PAS-M
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(Figure 5.4). This 5.3 °C increase in Tm suggests that PAS-M has a stabilizing effect on
FDTS by upon binding.

Figure 5.4. Differential scanning calorimetry (DSC) analysis of Mtb FDTS in complex with PAS-M

It has been shown that NADPH and mTHF occupy the same binding site. Due to this
overlap,

high

concentration

of

mTHF

has

an

inhibitory

effect

on

NADPH

concentration.14,15 Therefore, an inhibitor that competes for this binding site is likely to
also interrupt NADPH oxidation. With this idea in mind, we tested the inhibitory effect of
PAS-M, MTX, and lead PLAs on NADPH oxidation activity of FDTS by monitoring the
oxidation of NADPH at 340 nM. All the compounds were tested at 1:1 molar ratio with
NADPH (200 µM). mTHF was used as the positive control with 100% inhibition of NADPH
oxidation when it is present at 1:1 molar ratio with NADPH. Excitingly, PAS-M had an
inhibitory effect similar to mTHF and fully inhibited the NADPH oxidation (Figure 5.5 A).
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At the same concentration MTX showed almost 50% inhibition and no significant inhibition
was observed with PLAs (less than 5%).

Figure 5.5. Inhibition of NADPH oxidation activity of MtbFDTS by PAS-M, MTX and PLAs (A), and
dose-response inhibition of MtbFDTS by PAS-M

Inspired by this result, we performed a dose-response inhibition assay to determine
the IC50 of PAS-M for the NADPH oxidation reaction. The apparent IC50 was determined
to be 14.4 µM (Figure 5.5 B). It is important to note that due to the competition of PASM and NADPH, the IC50 value of PAS-M is dependent on the concentration of NADPH
and most likely an underestimation of its true inhibitory concentration.
Although NADPH oxidation assay is considered as a valid method to find inhibitors of
FDTS, to evaluate the ultimate effect of PAS-M on dTMP synthesis we performed HPLC
analysis to monitor the production of dTMP. Uninhibited reaction was used as the control
and samples were taken at different time points (0, 10, 20, and 30 minutes). Compared
to the control, there is a significant accumulation of dUMP and decrease in dTMP level
(~2.5 fold) when the reaction was incubated with PAS-M (Figure 5.6).
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Figure 5.6. HPLC analysis of Mtb FDTS reaction(A), and inhibitory effect of PAS-M on dTMP
synthesis

Altogether, the data suggests that PAS-M is in inhibitor of Mtb FDTS, most likely by
binding to the overlapping folate and NADPH binding site. By interrupting the oxidative
half-reaction of FDTS, PAS-M results in the inhibition of dTMP synthesis.
Our efforts to co-crystallize PAS-M with FDTS were not successful even when
attempting to soak PAS-M into the FDTS:FAD:dUMP complex. Despite obtaining single
3D crystals, the diffraction quality was too poor to solve the structure. However, we were
able to solve a FDTS structure bound to FAD and dUMP at 3.5 Å resolution. We used this
crystal structure for our structural analysis and for modelling PAS-M into FDTS binding
site.
The Mtb FDTS is a tetramer with each monomer composed of a central a/b domain,
flanked by two helical top and bottom domains. The four monomers come together to
form a tetrameric molecule with 222 symmetry and four active sites. The monomers are
labeled as a, b, c and d and shown with different colors in the Figure 5.7 A. It is interesting
to note that each active site of the Mtb FDTS tetramer is formed at the interface of three
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monomers (Figure 5.7 B). All the active sites are identical, therefore we describe only
one of the catalytic sites here.

Figure 5.7. Structure of MtbFDTS bound to FAD and dUMP. A) surface model of the tetrameric
MtbFDTS, B) The active site

The adenine ring of FAD is buried in a deep binding pocket in the enzyme (Figure 5.8).
The adenosine monophosphate (AMP) moiety of FAD is bound mostly via interactions
with the a and c subunits. The adenine ring interacts with His98 and Asn188 of subunit c
and the conserved Arg97 of subunit a. The ribose sugar of AMP is in contact with
conserved Arg190 of subunit c and His98 and His194 of subunit a. The phosphate of
AMP makes interactions with Arg97-His98-Phe99 tripeptide of subunit d. The phosphate
of flavin mononucleotide (FMN) moiety forms hydrogen bonds with the conserved Arg90
of subunit c and the conserved Arg97 and His194 of subunit a. All the oxygens of the
phosphate group of FMN are involved in strong hydrogen bonding interactions. The ribityl
group of FMN is in contact with Arg95 and Arg199 of subunit a and Ser71 of subunit c.
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The isoalloxazine ring forms hydrogen bonds with Arg95 of subunit a, Gln103 of subunit
d and Tyr144 of subunit c and stacks against the pyrimidine ring of dUMP.

Figure 5.8. FAD (yellow) and dUMP (magenta) binding sites of Mtb FDTS

These two rings are nearly coplanar with distances between the atoms of the rings
varying between 3.2 Å and 3.5 Å. Interestingly, the C5 carbon atom of dUMP, which is
the recipient of the methyl group, and the N5 nitrogen atom of FAD, which transfers the
hydride, are within 3.3 Å.
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dUMP is deeply buried in the binding site, interacting with numerous residues. The
phosphate group of dUMP is in contact with Arg87, Arg107, Arg172, Ser105, and Gln106
of subunit d and Glu92 of subunit a. The ribose sugar of dUMP interacts with the
conserved Arg95 of subunit a. The pyrimidine ring of dUMP makes several interactions
with the flavin ring of FAD and residues Asp205, Glu92, and Arg199 of subunit a and
Ser105 and Tyr108 of subunit d.

Figure 5.9. Modelling of PAS-M (brown) into Mtb FDTS:FAD:dUMP complex
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We then modelled PAS-M into the solved FDTS:FAD:dUMP complex using the
Schrödinger molecular modelling software. In this model, the pterin moiety of PAS-M is
stacked between the isoalloxazine ring of FAD (which itself is stacked against the
pyrimidine ring of dUMP) and the imidazole of His69 of subunit c (Figure 5.9). This
histidine residue is highly conserved among different species and its mutation has been
shown to decrease the catalytic activity of FDTS from Thermotoga maritima.13 The 2amino group of pteridine ring is 3.0 Å from Tyr44 of subunit c. The characteristic hydroxyl
group of PAS-M is 3.1 Å from the conserved Arg190 and 3.5 Å from the phosphate groups
of the FMN moiety of FAD. The carboxylate groups of the glutamate tail of PAS-M are
within hydrogen bond distance from Arg193, Arg190, and His194. We also assume that
water-mediated interactions would further improve PAS-M affinity for Mtb FDTS.

5.6

In vitro selection of PAS-resistant isolates

To better understand the mechanism of resistance to PAS, we performed in vitro selection
of PAS-resistant mutants by exposing the Mtb Erdman strain to PAS at concentrations
above MIC levels (Methods). The selected isolates, PAS-R1, PAS-R3, and PAS-R4 were
resistant to PAS with MIC levels ranging from 16-32 µg/mL (Table 5.2). We then
performed whole genome sequencing to determine the resistance mechanisms. Isolate
PAS-R1 showed a E153G mutation in folC gene which encodes for DHFS. Isolate PASR4 showed a I43T mutation also in folC. Both of these mutations have been previously
detected in PAS-resistant clinical isolates of Mtb and result in a nonfunctional DHFS
enzyme. The fact that two out of three resistant isolates showed folC mutations suggest
that one of the main mechanisms of resistance to PAS is through deactivation of folC and
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prevention of PAS-M production, confirming the importance of PAS bioactivation. Isolate
PAS-R3 showed a C to T mutation at position -16 upstream of the thyX gene. This
mutation has been shown to increase thyX expression by 18-fold and found to be
associated with resistance to PAS.
Table 5.2. Antimycobacterial activity of PAS, UCP1172 and UCP1175 against PAS-resistant Mtb
isolates
MIC (µg/mL)
Compounds
Mtb Erdman
PAS-R1
PAS-R3
PAS-R8
PAS

0.5

32

16

32

UCP1172

0.03

0.125

1

0.015

UCP1175

0.5

4

16

1

The experiments are performed in triplicates.

We also evaluated the potency of UCP1172 and UCP1175 against these PAS-resistant
isolates. UCP1172 exhibits potent inhibition of all the isolates, although at slightly higher
MIC (Table 5.2). Interestingly, isolate PAS-R3 with thyX mutation is the most resistant
one to PLAs, suggesting that thyX overexpression compensates for DHFR inhibition.

5.7

Inhibition of Mycolic Acids Biosynthesis

It has been previously shown that antifolate treatment in Mtb leads to the disruption of the
activated methyl cycle and the depletion of methionine and s-adenosylmethionine (SAM).
This disruption has consequences on production of reactive methyl groups required for
DNA methylation, polyamine biosynthesis and biotin production. In Mtb, SAM is
specifically necessary for the formation of keto- and methoxy-mycolic acids. To evaluate
the effect of folate pathway disruption by PAS and PLAs on the mycolic acid biosynthesis,

114

we performed 14C-acetate labeling of Erdman strain grown in the presence of PAS or the
lead PLA, UCP1172, which were added in early mid-log phase of growth in 0.36, 0.72
and 1.44 µg/ml final concentrations. The treatment with UCP1172, or PAS did not lead to
any dramatic alterations in synthesis of major phospholipids, trehalose monomycolates
or trehalose dimycolates (Figure 5.10), although total incorporation of

14

C into the

fractions of extracted lipids was reduced compared to the non-treated control to 83 % and
66 % by 0.72 and 1.44 µg/ml UCP1172 and to 82 % and 69 % by 0.36 and 0.72 µg/ml
PAS.

TDM

TMM
PE
CL
CTR 0.36 0.72 0.36 0.72 1.44 µg/ml
PAS

UCP1172
14

Figure 5.10. Autoradiograph of TLC analysis of lipids extracted from C acetate labeled Mtb Erdman
cells treated with UPC1172, PAS or DMSO as a control (CTR). The lipids were separated in
chloroform: methanol: water [20:4:0.5] and detected by autoradiography. (TMM: trehalose
monomycolates; TDM: trehalose dimycolates; PE: phosphatidylethanolamine; CL: cardiolipin).

Analysis of methyl esters of fatty acids and mycolic acids (FAME/MAME) extracted
from radiolabeled cells revealed important changes in PAS- treated and UCP1172-treated
mycobacteria including an overall reduction of the 14C incorporation to the FAME/MAME
fraction (namely 14, 36 and 56% reduction by 0.36, 0.72 and 1.44 µg/ml UCP1172 and
52% reduction by 0.36 and 0.72 µg/ml PAS) and qualitative changes as revealed by TLC.
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As shown on figure 6.10 A, PAS treatment leads to significant decrease of
methoxymycolic acids, the effect, which is found also upon UCP1172 treatment at the
highest concentration used. Further analysis of mycolic acids by argentation TLC
revealed appearance of other forms of mycolates, which are not present in non-treated
bacteria (Figure 5.11 A and B) for both drugs.
A.

B.

FAME

M
A
M
E

FAME

M
A
M
E

a
methoxy
keto

a
methoxy
keto
unsaturated
forms

CTR 0.36 0.72 0.36 0.72 1.44 µg/ml
PAS

CTR 0.36 0.72 0.36 0.72 1.44 µg/ml

UCP1172

PAS

UCP1172

Figure 5.11. Autoradiograph of standard (A) and argentation (B) TLC analysis of methyl esters of
14
fatty and mycolic acids isolated from C acetate labeled Mtb Erdman cells treated with UPC1171,
PAS or DMSO as a control (CTR). Different forms of methyl esters were separated in n-hexane/ethyl
acetate [95:5], 3 runs and detected by autoradiography. (FAME: fatty acyl methyl esters; MAME:
mycolic acid methyl esters; alpha, methoxy and keto refer to the forms of MAMEs).

Slower migration of these forms indicates the presence of mono- or diunsaturation in
their carbon chains. Since these forms of mycolic acids are precursors of methylated
mycolic acids (including alpha- and keto- mycolic acids) we conclude that both UCP1172
and PAS interfere with methylation of these precursors. It has been already shown that
disruption of folate pathway leads to perturbation of the activated methyl cycle and altered
regulation of genes involved in the biosynthesis and utilization of methionine and S-
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adenosyl methionine, including methyltransferases dependent on SAM.17 Thus we
conclude that the observed effects (decrease in methoxy-mycolates and accumulation of
unsaturated mycolates) is due to the lack of SAM for SAM-dependent methyltransferases
involved in the modifications of mycolic acids.

5.8

Conclusions

Misincorporation of PAS into the folate pathway results in the formation of its bioactive
metabolite (PAS-M) by the sequential action of DHPS and DHFS. This metabolite, the
structural analog of DHF, has been suggested to inhibit DHFR. Here, we have shown that
PAS-M is a weak inhibitor of DHFR and it is unlikely that PAS antimycobacterial activity
is due to DHFR inhibition. However, our results show that PAS-M is an inhibitor of FDTS,
an unusual thymidylate synthase found in Mtb. By inhibiting the FDTS oxidative reaction,
PAS-M results in a significant decrease in dTMP synthesis. Our structural analysis has
revealed key structural features of PAS-M that facilitates its binding to the FDTS active
site. Due to the direct link between the folate pathway and activated methyl cycle, we
have also shown that antifolate treatment leads to the disruption of methyl cycle and,
ultimately, mycolic acid synthesis. Our finding suggests that PAS exerts its
antimycobacterial activity by general poisoning of the folate pathway rather than acting
on a single target.
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6
6.1

Non-Tuberculous Mycobacteria
Preface

The work presented in this chapter is taken from the following publications:

Hajian, B., Shoen, C., Cynamon, M., Wright, D. Propargyl-Linked
Antifolates

Are

the

Inhibitors

of

Mycobacterium

avium

Folate

Biosynthetic Pathway. 2018. Unpublished manuscript.

Contributions: The compounds design and synthesis was done by Eric Scocchera and
Santosh Keshipeddy. Antimycobacterial susceptibility testing was done by Carolyn
Shoen. My contribution to the work discussed in this chapter was experimental design,
Ma DHFR transformation, expression, purification, and characterization, performing
enzyme inhibition assays, data analysis, and writing the manuscripts.
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6.2

Introduction

The Mycobacterium genus is divided into three groups: Mycobacterium tuberculosis
complex (MTBC), Mycobacterium leprae and the remainder, collectively called nontuberculosis mycobacteria (NTM). NTM are a large family of environmental
microorganisms that are mostly non-pathogenic, but some can cause human diseases.
Although the distribution of NTM species varies by geography, Mycobacterium avium
complex (MAC) is the most common pathogen in most areas followed by M. abscessus
complex (MABC) and M. kansasii. In children, NTM infections usually result in cervical
lymphadenitis, skin and osteoarticular infections, lung disease and disseminated
infections.1,2
NTM and MTBC share similar microbiological characteristics, induce similar immune
responses, and have overlapping clinical manifestations. Diagnosis of NTM is very
challenging and cannot be distinguished from TB on the basis of clinical history, tuberculin
skin test, radiological patterns, and smear microscopy.3 Diagnosis is specially challenging
in children living in region where TB is highly endemic. The underlying diagnosis is most
often assumed to be childhood TB and is followed by standard TB treatment. However,
the treatment of NTM is very different from that of TB.4
6.2.1 Burden of NTM infections
National surveillance studies of NTM disease are uncommon, and most countries do not
do systematic reporting of the occurrence of NTM disease. However, results from different
studies have shown an increase in NTM isolates and disease in the past decades. The
incidence and prevalence of NTM lung disease continue to increase worldwide, leading
to an emerging public health problem. A thorough state-specific study have shown that
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although NTM is a relatively rare disease, the associated financial burden in the United
States is substantial with total cost of $815 million for 86,244 cases in 2010. Nearly 80%
of this cost is attributed to prescription medication costs due to the chronic nature of the
disease and complicated antibiotic regimens.2,5
6.2.2 Transmission of NTM
The mechanism of NTM transmission is not fully understood. Aerosol inhalation from
municipal or private water systems is thought to be an important route of acquisition.
Water transmission of NTM has been supported by studies that showed the same genetic
composition of MAC isolates in pulmonary secretions and the household water systems.
The presence of MAC in shower biofilms in the USA further confirms the constant
exposure of people to NTM. Nosocomial NTM outbreaks in paediatric patients who have
received haematopoietic cell and bone marrow transplants has been associated with
hospitals water supply. Human-to human transmission has been also reported in patients
with cystic fibrosis admitted to a health-care center.6,7
6.2.3 Risk factors
Cystic fibrosis and mendelian susceptibility to mycobacterial disease (MSMD) are two
distinct inborn genetic disorders associated with NTM disease. NTM is also associated
with HIV infection and very low CD4 cell counts in both adults and children. NTM diseases
have been also reported in recipients of organ transplants or haematopoietic stem cell
transplants, patients receiving immune therapies directed against T cells, and paediatric
patients with cancer, in whom bloodstream NTM infections are associated with the use of
central venous catheters. In adults, a previous history of TB is also a risk factor for
pulmonary NTM infection, probably due to structural damage of the lung.1,8
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6.2.4 Host-pathogen interactions
In immunocompetent host, NTM are unlikely to cause disease and the host immune
system is usually capable of containing and possibly eradicating NTM via innate ad
acquired immune mechanisms. Most of our current knowledge about protective immune
mechanisms against NTM have come from studies of patients with MSMD. MSMD is a
rare genetic syndrome characterized by predisposition to clinical infections caused by
NTM and BCG. Nine MSMD-causing mutations have been identified in seven autosomal
recessive and two X-linked genes. The products of these nine genes are physiologically
related as all are involved in IFN-g dependent immunity. Identification of these genes have
substantially informed our understanding of human response to mycobacterial infection,
which relies on the integrity of the helper T cell type 1-cytokine pathway. Disruption of this
pathway render the host susceptible to weakly pathogenic mycobacteria.8
6.2.5 Treatment of NTM
NTM frequently develops resistance to antimicrobial drugs, therefore management of the
disease relies on combination of several antibiotics, with macrolides (clarithromycin and
azithromycin) being the core of the regimen. Treatments are lengthy and complicated with
drug intolerance and severe side effects. Child-friendly formulations are not available for
most NTM drugs, causing poor adherence and prognosis. In addition, low availability of
drugs, even mainstream TB drugs such as rifampicin and ethambutol, makes the
treatment even more challenging.9,10
Treatment of MAC pulmonary disease consists of a combination of macrolides,
ethambutol, and a rifamycin (rifampin or rifabutin), with streptomycin or amikacin
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sometimes added, for 18-24 months. Treatment of M. Kansasii lung disease includes
rifampicin, isoniazid, and ethambutol.1,3
Some of the other antibiotics that are used for treatment of NTM include linezolid, used
for treatment of MDR TB, clofazimine, an anti-leprosy drug, and bedaquiline, an oral MDR
TB drug.10,11
Treatment option of NTM lymphadenitis varies from conservative strategies for mild
cases to complete surgical excision of the affected lymph node. Currently, the surgical
approach is regarded as the best curative option by most clinicians. However, permanent
injury of the facial nerve is a major concern with surgery.1
Overall, except for M. Kansasii, NTM lung disease is difficult to control with
antimicrobial therapy alone. Surgical approaches can be effective in cases of significant
drug resistance or failure of medical treatment.

6.3

Mycobacterium avium complex (MAC)

The most prevalent and important group of NTM is MAC which includes M. avium, M.
intracellulare and M. chimaera species. MAC can cause life-threatening systemic
infections

in

immunocompromised

people

especially

those

with

acquired

immunodeficiency syndrome (AIDS). Although some success has been achieved by
combination therapy, lengthy and expensive regimen, severe side effects, and the
resistant nature of MAC emphasizes the need for new drugs.2
Like almost all other microorganisms, the folate pathway is essential in MAC by
providing reduced folates as the sources of one-carbon donor for the synthesis of dTMP,
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methionine, histidine and purines. Inhibition of the folate pathway by antifolates has been
widely used a s an effective strategy for treatment of various infectious and neoplastic
diseases.12
MAC is intrinsically resistant to the antifolate trimethoprim (TMP) with the IC50 values
of 4.1 µM.13,14 TMP is an inhibitor of dihydrofolate reductase (DHFR), a key enzyme in
the folate pathway the catalyzes the NADP-dependent reduction of dihydrofolate (DHF)
to tetrahydrofolate (THF) (Chapter 3). TMP is generally used in combination with
sulfamethoxazole (SMX) to treat infections caused by Gram-positive and Gram-negative
bacteria.15
Although antifolates have not been utilized for treatment of MAC infections, recent studies
have identified a class of 2,4-diamino-5-deazapteridine inhibitors of MAC with IC50 values
close to 1 nM.16 One of these compounds has also shown to be synergistic against MAC
when used in combination with SMX and dapsone.17

6.4

Activity of PLAs against MAC

Inspired by our previous findings on the antimycobacterial activity of propargyl-linked
antifolates (PLAs) and potent Mtb DHFR inhibition, we decided to evaluate the cytotoxicity
of lead PLAs against MAC in vitro growth.
We tested the growth inhibitory effect of UCP1172 and UCP1175 against a panel of
MAC isolates in comparison to clarithromycin, one of the core macrolides used in
treatment of NTM infections. Excitingly, UCP1172 is a very potent inhibitor of all the MAC
isolates with MIC values ranging from 0.008 to 0.125 µg/mL (Table 6.1). MIC values for
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UCP1175 are also promising although the compound is not as potent as UCP1172. The
MIC values suggest that UCP1172 and UCP1175 do not face permeability issues through
MAC cell wall.
Table 6.1. The antimicrobial activity of clarithromycin, UCP1172 and UCP1175 against MAC
isolates
MIC (m g/mL)
Isolates
Clarithromycin
UCP1172
UCP1175
MAC LPR

0.5

0.125

16

MAC 3404.4

0.125

0.004

0.06

MAC TEL

1

0.06

4

MAC JWT 005B

128

0.03

2

MAC 623

64

0.03

4

MAC 101

128

0.008

1

MAC KAL

128

0.008

1

The experiments are performed in triplicates.

Although our previous knowledge about anti-DHFR activity of PLAs suggest that their
growth inhibitory effect against MAC isolates is also due to inhibition of MAC DHFR,
further enzyme assays are required to determine the precise mechanism of action.

6.5

Mycobacterium avium DHFR

MAC DHFR, encoded by folA gene, share ~70% protein sequence identity with Mtb DHFR
(Figure 6.1). The active site of the two proteins is essentially identical (Figure 6.2). In Ma
DHFR, Asp31 and Arg64 correspond to the conserved Asp27 and Arg60 in Mtb DHFR,
respectively. Site-directed mutagenesis of Asp31 has shown that this residue is critical
for the catalytic activity of Ma DHFR.14
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Figure 6.1. Protein sequence alignment of Mtb DHFR and Ma DHFR

Superposition of Mtb DHFR bound to UCP1172 and Ma DHFR bound to TMP (PDB
ID: 2W3V) suggest that UCP1172 is most likely having very similar interactions with Ma
DHFR (Figure 6.2), while TMP seems to be too far from the main residues of the active
site to form direct hydrogen bonds.

Figure 6.2. Superposition of MaDHFR:NADPH:TMP (teal) and MtbDHFR:NADPH:UCP1172 (blue)
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We purified Ma DHFR which was cloned in pET-24a(+) plasmid and expressed in E.
coli BL21 cell line. The pure protein was used to perform enzyme inhibition assay for
UCP1172 and UCP1175. The uninhibited reaction was used as the control to determine
the IC50 values (Table 6.2).
Table 6.2. Inhibition of Ma DHFR by UCP1172 and UCP1175
Enzyme
Ma DHFR

IC50 (nM)
UCP1172

UCP1175

150 ± 10

812 ± 22

UCP1172 is a more potent inhibitor of Ma DHFR comparing to UCP1175. Although this
difference in the IC50 value of two PLAs correlates with the difference in their MIC values,
overall this level of enzyme inhibition does not seem potent enough for the outstanding
MIC level of UCP1172. This suggest that either the IC50 values are not reflecting the true
affinity of this compound or the antimicrobial effect of UCP1172 is not solely due to the
DHFR inhibition. Further assay optimization and determination of kinetics parameters
such as dissociation rate is necessary to address these questions.

6.6

Conclusions

The prevalence of NTM infections is increasing worldwide, even in immunocompetent
individuals.5 Management of NTM lung disease is mainly carried out by lengthy,
expensive, and sometimes ineffective drug regimens. Microbiological eradication using
currently available antibiotic regimens is difficult and recurrence is common even after
successful completion of NTM treatment. To address the problems associated with
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current NTM treatment there is a need for discovery and development of optimal
therapeutic regimens and effective agents with less side effects.1,7
Antifolates are a class of chemicals that have been widely used for treatment of
infectious diseases and different types of cancer. Antifolates exert their effect by
interruption of the folate biosynthetic pathway, resulting in depletion of reduced folates
that are required for cell function and survival.15
Here, we have investigated the antimicrobial effect of propargyl-linked antifolates
(PLAs), a novel class of antifolates,18,19 against a panel of Mycobacterium avium complex
(MAC), the most prevalent group of NTM. Excitingly, UCP1172 exhibit excellent inhibitory
effect against the in vitro growth of a panel of MAC isolates with MIC values far more
potent than clarithromycin, one of the core macrolides used in treatment of NTM.
Although our initial enzyme inhibition assay suggests that UCP1172 is a DHFR
inhibitor, further investigation is required to determine its precise mechanism of action. In
addition, our comparative genomics analysis has shown the presence of Rv2671 and
flavin-dependent thymidylate synthase (FDTS) homologues in MAC. Characterization of
these protein will aid us in elucidating the inhibitory mechanism of UCP1172.
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7

Final Discussion and Future Directions

Identification of Mycobacterium tuberculosis (Mtb) in 1882 was the steppingstone toward
understanding and treating tuberculosis (TB), one of the most devastating diseases of
humankind. 130 years down the road, despite the discovery of potent antibiotics and
overall improvement of public health, TB remains an enormous global health problem.
Lengthy and complex drug regimens, emergence of drug resistance, and TB/HIV coinfection are the main challenges to the global control of TB. Novel anti-TB agents are
required to address the issues associated with the current drug regimens and to improve
the outcomes of TB therapy.1–4
Propargyl-Linked antifolates (PLAs), are a class of small molecules designed to disrupt
the essential folate pathway by inhibiting DHFR enzyme in a variety of infectious
microorganisms.5,6 Interruption of the folate pathway is detrimental to cell survival by
critical depletion of reduced folates required for nucleic acid and protein synthesis.7
Although antifolates and DHFR inhibitors have been widely used for treatment of
infectious diseases and different types of malignancies, they are underutilized as anti-TB
agents. Our objective was to evaluate the potential of PLAs as antimycobacterial agents
and identify compounds that are selective inhibitors of Mtb DHFR and potent inhibitors of
in vitro growth of Mtb with adequate physicochemical and kinetics properties that might
be suitable for future testing in animal models of TB infection.
We were able to identify a few potent inhibitors of drug-susceptible Mtb Erdman strain
as well as MDR and XDR clinical isolates. These compounds that feature a carboxylic
acid moiety are potent inhibitors of Mtb DHFR with moderate selectivity toward human
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form of the enzyme. The lead PLA, UCP1172, is an excellent inhibitor of both in vitro
growth of the bacteria (MIC value of 0.03 µg/mL) and DHFR enzymatic activity (IC50 value
of 10 nM). Methotrexate, a potent Mtb DHFR inhibitor, fails to inhibit the growth of live
microorganism, most likely due to the lack of permeability through the mycolic acid-loaded
cell wall of Mycobacteria.8
Analysis of drug-target interactions, have revealed key structural features that drive the
potency of PLAs for Mtb DHFR. 2,4-diaminopyrimidine ring, propargylic methyl, and paracarboxylate moieties of the PLAs form strong interactions with the active site residues
and locks the inhibitor in its position. This was also confirmed by the slow dissociation
rate of UCP1172 and its long residence time of 40 minutes on Mtb DHFR.
Here, we have also shown that PLAs are dual inhibitors of Mtb DHFR and Rv2671, an
alternative DHFR found in Mtb cells. Overexpression of Rv2671 is associated with clinical
PAS resistance most likely by overriding the inhibition of canonical DHFR.9–12 Therefore,
the dual inhibitory activity of PLAs is valuable in the design of novel DHFR inhibitors
against drug-susceptible and drug-resistant TB.
Along with the design of novel scaffolds, understanding the mechanism of action of
existing drugs will aid us in studying the patterns of resistance and the design of
compounds to circumvent this issue. To fulfill this goal, we compared the
antimycobacterial activity of lead PLAs to para-aminosalicylic acid (PAS), a second-line
anti TB drug. PAS is a competitive substrate for DHPS and has been recently suggested
to act as a prodrug for Mtb DHFR.10,13 Our results have shown that PAS metabolite (PASM) is a weak inhibitor of Mtb DHFR with IC50 value of 10 µM and a short residence time
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of 1.5 minutes. Our structural analysis has shown unoptimized interactions between this
metabolite and Mtb DHFR, supporting the idea that this compound is not a potent inhibitor
of this enzyme.
In search of its mechanism of action, we have found that PAS-M acts as an inhibitor of
FTDS, an unusual thymidylate synthase found in Mtb. Although it is not clear why Mtb is
equipped with two thymidylate synthases (TS and FDTS), it has been shown that FDTS
is essential for Mtb survival.14 Inhibition of FDTS by PAS-M results in a significant
decrease in the level of dTMP, the final product of FDTS reaction. To our knowledge,
inhibition of FDTS by PAS-M as part of PAS mechanism of action has not been reported.
The folate biosynthetic pathway is closely linked to activated methyl cycle by providing
mTHF and N5-methyl THF as the one-carbon donors for the synthesis of methionine and
s-adenosylmethionine (SAM). SAM is further used as the methyl donor in the methylation
of DNA, RNA, proteins, lipids and mycolic acid synthesis.8,15 Therefore, the downstream
effects of the interrupted folate pathway are manifold and include changes in many
essential cell functions. Here, we have shown that treatment of Mtb cells with PAS and
UCP1172 results in a dramatic decrease in the level of methylated precursors of mycolic
acid synthesis.
Comparison of PLAs and PAS have aid us to gain insight into the mechanism of action
of both class of chemicals. In the light of these observations, we conclude that PLAs exert
their antimycobacterial activity by potent dual inhibition of Mtb DHFR and Rv2671. We
believe that the carboxylate moiety of these compounds facilitates their permeation
through the Mtb cell wall. The long residence time on DHFR and slow dissociation from
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the target, improves the growth inhibitory activity of PLAs and makes them excellent
candidates for future in vivo studies.
On the other hand, we suggest that PAS cytotoxicity on Mtb cells is due to the general
poisoning of the folate metabolism by interruption of a few key steps along the pathway
rather than acting on a single target. Ultimately, both of these mechanisms lead to the
interruption of key cellular functions and arrest of the bacterial cell growth.
We have also shown that UCP1172 is a potent inhibitor of Mycobacterium avium
complex (MAC), the most prevalent group of pathogenic non-tuberculous mycobacteria
(NTM). Drug regimens for the treatment of NTM are lengthy, complex, and expensive and
sometimes ineffective to drug resistance.
Our findings suggest that inhibition of folate pathway is a valid strategy for halting the
growth and proliferation of Mtb and MAC cells. Continued efforts to identify novel
antifolates and understand the effects of folate pathway inhibition will allow rational design
and optimization of inhibitors of folate metabolism as effective anti-TB agents.
Although the folate pathway has been studied for more than 50 years, the presence of
unique enzymes in mycobacterial folate pathway suggest that the established paradigms
may not entirely apply to mycobacteria, providing us with unique challenges to confront
and unique opportunities to exploit.
TB is now found in every corner of the globe and no population is immune or isolated
from this risk. However, in the past decade, development of fast and affordable genomics
and biomedical technologies and the growth of shared databases, have accelerated the
process of drug discovery and development for many diseases including TB and NTM
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infections. As our understanding of TB increases and the pipeline of antimycobacterial
agents expands, we have reasons to be optimistic that the challenges of TB drug research
and development are surmountable, and a new revolutionary road for treatment of TB will
soon become a reality.
However, any new drug or vaccine for TB and NTM will fail to make a significant impact
if it is not accompanied by proper support of regulatory agencies and governments of
developed countries, and emerging economies to ensure the proper access of these
drugs to the patients most in need in resource-poor countries.

Human beings are members of a whole,
In creation of one essence and soul.
If one member is afflicted with pain,
Other members uneasy will remain.
If no sympathy for human pain,
The name of human we won’t retain.
Saadi Shirazi, 1210-1291
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8.1

Materials and Methods
Chemicals

Isoniazid, trimethoprim, methotrexate, clarithromycin, FAD, and DHF were purchased
from Sigma Chemical Co., St. Louis, MO. NADPH and dUMP were purchased from Alfa
Aesar, Tewksbury, MA. PLAs were dissolved in 100 % DMSO to a concentration of 20
mg/ml.

8.2

Isolates

M. tuberculosis ATCC 35801 (strain Erdman) was obtained from the American Type
Culture Collection, Manasas, VA. Clinical isolates were obtained from SUNY Upstate
Medical University, Syracuse, NY (provided by Betz Forbes), University of Stellenbosch,
South Africa (provided by Tommy Victor), National Center of Tuberculosis and Lung
Diseases of Georgia, Tbilisi, Georgia (provided by Natalia Shubladze), National Jewish
Center, Denver, CO (provided by Leonid Heifets).
The mycobacterial isolates were grown in modified Middlebrook 7H10 broth (pH6.6; 7H10
agar formulation with agar and malachite green omitted) supplemented with 10%
Middlebrook oleic acid-albumin-dextrose-catalase enrichment (Difco Laboratories,
Detroit, MI) and 0.05% Tween 80 on a rotary shaker at 37 0C for 5-10 days. The
organisms were diluted in 7H10 broth to 1 Klett unit (equivalent to about 5 X 105 CFU/ml)
using a Photoelectric Colorimeter (Manostat Corp., New York, NY) for use in the broth
dilution assay.
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8.3

In vitro Susceptibility Testing

Polystyrene 96-well round-bottom microtiter plates (Corning Inc., Corning, NY) were filled
with 50 µl of modified 7H10 broth. The compounds were prepared at 4 times the maximum
concentration at which they were to be tested and then were added to the first well prior
to being serially diluted 2-fold. INH was tested using a range of concentrations from 8
µg/ml- 0.008 µg/ml. The DHFR inhibitors were tested using a range of 32 µg/ml to 0.03
µg/ml. The inocula used for each strain were measured by titration and plated on 7H10
agar plates to determine the actual inocula. The 7H10 agar plates were incubated at 37
0

C for 4 weeks. Fifty microliters of the inocula was added to each well containing

compound to yield an initial concentration of about 2.5 x 105 CFU/ml (range for various
isolates tested was 1.25 X 106 CFU/ml – 8 X 104 CFU/ml). The microtiter plates were
covered with SealPlate adhesive sealing film (Exel Scientific, Wrightwood, CA) and were
incubated at 37 °C in ambient air for 14-21 days prior to reading. Each isolate was tested
in duplicate. The MIC was defined as the lowest concentration of antimicrobial agent
yielding no visible turbidity.1

8.4

Expression and Purification of Mtb DHFR, Ma DHFR, Hu DHFR (no His-tag)

BL21(DE3) competent E. coli cells (New England BioLabs) were transformed with
recombinant plasmids harboring the dfrA gene constructed by GenScript. Transformed
cells were grown in LB medium supplemented with 30 µg/mL kanamycin at 37 °C until
the OD600 reached 0.6-0.7. The cells were induced with 1mM IPTG for 20 h at 20°C and
spun down at 8000 rpm for 15 minutes. Each gram of wet cell pellet was resuspended in
5 ml of 1X BugBuster reagent (Novagen) supplemented with 200 µg/mL lysozyme and
142

1mM DNase I (Thermo Scientific). The cell suspension was incubated for 30 minutes at
room temperature with gentle rotation followed by 5 minutes sonication at 50% amplitude,
and centrifugation at 18,000 rpm for 30 minutes and supernatant was collected. In order
to precipitate some of non-target proteins, 40% ammonium sulfate was added to the cell
lysate and stirred at 4°C overnight. After centrifugation at 18,000 rpm for 15 minutes, the
supernatant was passed through 0.22 µm filter and slowly loaded onto a methotrexateagarose column pre-equilibrated with 4 CV of equilibration buffer A (20 mM Tris-HCl,
50mM KCl, 2mM DTT, 0.1 mM EDTA and 15% (v/v) glycerol, pH 7.5). The column was
washed with 3 CV of wash buffer B (20 mM Tris-HCl, 500 mM KCl, 2 mM DTT, 0.1 M
EDTA and 15% (v/v) glycerol, pH 7.5). The enzyme was eluted with 3 CV of elution buffer
C (20 mM Tris-HCl, 50 mM KCl, 2 mM DTT, 2mM DHF, 0.1 mM EDTA and 15% (v/v)
glycerol, pH 8.5). Fractions containing DHFR enzyme, were collected, concentrated and
loaded onto a Hi-Prep 26/60 Sephacryl s-200 HR column pre-equilibrated with 1 CV of
equilibration buffer A (pH 8.5). The protein elution was monitored with AKTA UV/vis diode
array spectrophotometer at 280 nm. Fractions containing pure enzyme were pooled,
concentrated to 10 mg/ml and flash frozen in liquid nitrogen and stored at -80 °C.2

8.5

Expression and Purification of Mtb Rv2671, Mtb FDTS (with His-tag)

Recombinant plasmids harboring genes encoding Mtb Rv2671 and Mtb FDTS were
constructed by GenScript. BL21(DE3) competent E. Coli cells (New England BioLabs)
were transformed with the recombinant plasmids, separately. Transformed cells were
grown in LB medium supplemented with 30 mg/mL kanamycin at 37 °C until
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OD600 reached 0.6-0.7. The cells were induced with 1 mM IPTG for 20 hours at 20 °C and
spun down at 8000 rpm for 15 minutes. Each gram of wet cell pellet was resuspended in
5 mL of lysis buffer (25 mM Tris pH 8.0, 0.4 M KCl, 5 mM imidazole, 5 mM imidazole,
5 mM BME, 5% glycerol, 200 mg/mL lysozyme, 1 mM DNase I). The cell suspension was
incubated for 30-60 minutes at 4 °C with gentle rotation followed by sonication until a
homogenous lysate was obtained. The lysate was centrifuged at 18,000 rpm for 30
minutes and supernatant was collected and filtered through 0.22 mm filter. Mtb Rv2671
and Mtb FDTS constructs had a histidine tag and were purified using Ni-NTA purification
system (Thermo Scientific). The cell lysate supernatant was loaded over the column
packed with HisPur Ni-NTA Superflow Agarose beads and washed with 5 CV of buffer A
(25 mM Tris pH 8.0, 0.4 M KCl, 5 mM imidazole, 5 mM BME and 5% glycerol). The protein
was eluted with a gradient of buffer B (25 mM Tris pH 8.0, 0.3 M KCl, 250 mM imidazole,
5 mM BME, 0.1 mM EDTA and 20% glycerol). For all the purifications, fractions containing
DHFR protein were collected, concentrated and loaded onto a Hi-Prep 26/60 Sephacryl s200 HR prepacked gel filtration/size exclusion column pre-equilibrated with 1 CV of final
buffer (25 mM Tris pH 8.0, 50 mM KCl, 0.1 mM EDTA, 2 mM DTT and 15% glycerol). The
column was washed with another 1 CV of final buffer and protein elution was monitored
with AKTA UV/vis diode array spectrophotometer at 280 nm. Fractions containing pure
enzyme were pooled, concentrated at 10 mg/mL and flash frozen in liquid nitrogen and
stored at -80 °C.3,4
8.6

Michaelis-Menten Kinetics

Km values for NADPH and DHF and Vmax were obtained by varying each substrate
concentration in the presence of a fixed saturating concentration of the other one in in
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500 m L of assay buffer containing 20 mM TES, 50 mM KCl, 0.5 mM EDTA, 10 mM 2mercaptoethanol (BME) and 1 mg/mL bovine serum albumin (BSA). The kinetic
parameters were obtained through nonlinear curve fitting to Michaelis-Menten equation
(Equation 8.1) using GraphPad Prism 7.0.
𝑣=

#$%& '
($) '

(Equation 8.1)

Kcat was determined from Vmax using Equation 8.2, where [Et] is the total enzyme
concentration.5
𝐾𝑐𝑎𝑡 =

8.7

#$%&
[D9]

(Equation 8.2)

Enzyme Inhibition Assays

The normal DHFR activity of Mtb DHFR, Hu DHFR, Ma DHFR, and Mtb Rv2671 was
measured in 500 m L of assay buffer containing 100 m M NADPH, 20 mM TES, 50 mM KCl,
0.5 mM EDTA, 10 mM 2-mercaptoethanol (BME), 1 mg/mL bovine serum albumin (BSA)
and appropriate amount of the enzyme. Assay was started by adding 100 m M DHF and
monitoring NADPH oxidation at 340 nm. All measurements were performed at room
temperature and in triplicates. The DHFR activity inhibition assays and IC50 determination
were performed in the same assay buffer with 100 µM NADPH and 100 µM DHF. For
MtbRv2671 50 µM NADPH was used instead of 100 µM. Inhibitors, dissolved in 100%
DMSO, were added to the mixture and incubated for 5 minutes prior to adding DHF.5
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8.8

Crystallization of Mtb DHFR

Freshly purified protein in buffer A containing 5% glycerol instead of 15%, was incubated
with 5 mM NADPH and 2 mM inhibitor for two hours on ice. After incubation, the protein
solution was concentrated to 8 mg/mL and crystallized by hanging drop vapor diffusion
method and using EasyXtal 15-well plates (Qiagen). An equal volume of
protein:ligand:cofactor complex was mixed with crystallization solution (2 µl +2 µl ) and
let to equilibrate against 500 µl of well solution at 4 °C. Pyrimidal crystals suitable for data
collection grew to a size of 0.5 mm x 0.4 mm x 0.3 mm within 8 over 8 weeks from
solutions comprising 2.1-2.3 M (NH4)2SO4 and 0.1 M NaAc pH 4.5. Crystals were flashfrozen in the mother liquor supplemented with 20% glycerol. X-ray data were collected at
Stanford Synchrotron Radiation Lightsource (SSRL). Data were indexed and scaled using
HKL2000. Structure were solved by molecular replacement using the Phaser using
previously reported complex of MtbDHFR:NADPH:trimetrexate (PDB ID: 4M2X). The
programs Coot and Phenix were used for structure refinement.2,6

8.9

Drug-Target Residence Time Assay

Enzyme was incubated with inhibitor (at concentration 10 times higher than IC50) for 16
hours at 4°C in the absence of substrate. The mixture was then diluted 100-fold to stablish
the final inhibitor concentration well below the IC50 into an assay mixture containing 100
mM DHF and 100 mM NADPH. Enzymatic activity recovery was followed by monitoring
NADPH oxidation at 340 nM for 60 minutes. Data was fit into Equation 8.3 using the
uninhibited velocity as Vs. As no additional background NADPH oxidation occurs in the
absence of enzyme, V0 was set to zero. The residence time was calculated as the
146

reciprocal of the observed activity recovery rate constant, kobs, as described in Equation
8.4.7–12
𝑃 = 𝑉, 𝑡 +

#/ 0#1

𝑡; =

2341
<
23==

(1 − 𝑒 02341 9 )

=

<
2>?,

(Equation 8.3)

(Equation 8.4)

8.10 FDTS NADPH Oxidation Assay
FDTS NADPH oxidation assay was performed by monitoring NADPH oxidation at 340 nM
using Genesys 150 UV-Vis spectrophotometer from Thermo Scientific. The assay buffer
contained 100 mM dUMP, 50 mM FAD, 200 mM NADPH, 10 mM mTHF, and various
concentrations of inhibitors (for inhibition assay). The assay was initiated by adding the
enzyme at 10 mM final concentration. The assay was done in triplicates and each reaction
was followed for 15 minutes.13–16

8.11 Crystallization of HuDHFR
HuDHFR was mixed with 10 mM NADPH and 2 mM ligand, incubated on ice for two hours
and concentrated to 12 mg/mL. 2 µL of this solution was mixed with 2 µL of crystallization
solutions containing 0.1 M Tris pH 7-7.5, 0.2-0.4 M Li2SO4, 25-35% PEG 4K and
7% EtOH. Large hexagonal crystals grew within 1-2 weeks at 4°C. Crystals were flashfrozen in the mother liquor supplemented with 20% glycerol. X-ray data were collected at
Stanford Synchrotron Radiation Lightsource (SSRL). Data were indexed and scaled using
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HKL2000. Structure were solved by molecular replacement using the Phaser17 using
previously reported complex of HuDHFR:NADPH:UCP1006 (PDB ID: 4KAK).18 The
programs Coot19 and Phenix20 were used for structure refinement.

8.12 Crystallization of Mtb Rv2671
Mtb Rv2671 was mixed with 5 mM NADPH and 2 mM ligand, incubated at 4°C overnight
and concentrated to 5 mg/mL. 2 µL of crystallization solutions containing 0.1-0.3 M NaCl,
0.1 M Bis-Tris pH 5.5-7.5 and 20-30% PEG 3350 was mixed with 2 µL of protein solution
and equilibrated against the well solution at 18°C. Needle crystals grew within 2
weeks. Crystals were flash frozen in the mother liquor supplemented with 20% glycerol.
X-ray data was collected at National Synchrotron Light Source II (NSLS II) at Brookhaven
National Laboratory. Structures were solved by molecular replacement using the
Phaser17 and previously reported complexes.3 The programs Coot19 and Phenix20 were
used for structure refinement.

8.13 Crystallization of Mtb FDTS
The ternary complex of FDTS with FAD, and dUMP was prepared by mixing the enzyme
with a two-fold molar excess of FAD and ten-fold molar excess of dUMP, respectively.
Prior to crystallization the complex was incubated at 4 °C for 18 hours and then
concentrated

to

12

mg/ml

byultrafiltration
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using

Amicon

Ultracel-10K

filters

(Millipore). Crystals were obtained by the hanging-drop vapor diffusion technique. An
equal volume of the thyX-Leucovorin complex solution was mixed with a reservoir solution
containing 18% PEG 8K, 0.15 M MgCl2, 0.1M Na Acetate pH 5.0 and 2 mM DTT, at 4°C.
Initially, a shower of small crystals appeared in drops after 1 to 2 days. To delay the onset
of crystallization and to reduce number of crystals, an oil barrier (100 ul of 1:1 Paraffin:
Silicon Oil mix) was applied over the reservoir solution in the standard hanging drops
plates. Because of the favorable kinetics this process provided, larger and well-defined
crystals were obtained after a week. Prior to data collection, crystals were soaked in the
artificial mother liquor solution supplemented with 20% glycerol (v/v) and cryo-cooled in
liquid nitrogen. X-ray data were collected at Stanford Synchrotron Radiation Lightsource
(SSRL). Structure were solved by molecular replacement using the Phaser17 using
previously reported complexes.21 The programs Coot19 and Phenix20 were used for
structure refinement.

8.14 Differential Scanning Calorimetry (DSC)
In order to determine whether ligand binding to MtbDHFR is stabilizing or destabilizing,
we performed Differential Scanning Calorimetry (DSC) experiments on 1:1 mol ratio
of protein:ligand incubated samples using a Nano-DSC instrument (TA instruments).
600 uL of MtbDHFR at a concentration of 12 uM including NADPH and ligands or just
NADPH were heated 1ºC/min starting at 0 ºC and up to 120 ºC. All samples were
degassed extensively prior to injection into the calorimeter cell in order to prevent
formation of air bubbles. The reference cell was filled with buffer for all runs. A pressure
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of 3atm was applied to both cells during the run. The excess heat capacity scans for the
protein transitions were obtained by subtracting a control scan of buffer versus buffer.
The data were corrected for the difference in heat capacity between the initial and the
final state by using a sigmoid baseline in the NanoAnalyze software (TA instruments).

8.15 In vitro Generation of PAS-Resistant Mtb Isolates
The PAS-resistant mutants Mtb PAS-R1, Mtb PAS-R3, and Mtb PAS-R8 were generated
by growing M. tuberculosis Erdman (ATCC 35801) in modified 7H10 broth (pH 6.6; 7H10
agar formulation with agar and malachite green omitted) with 10% OADC (oleic acid,
albumin, dextrose, catalase) enrichment (BBL Microbiology Systems, Cockeysville, MD)
and 0.05% Tween 80 with 64µg/ml of PAS added on a rotary shaker at 37oC for 14 days.
After 14 days of incubation 1 ml of the broth was placed onto ten 7H10 agar plates with
10% OADC and 64µg/ml of PAS. After 4 weeks of incubation at 37oC several colonies
were selected, grown in 7H10 broth with 10% OADC, and tested for PAS resistance in a
microtiter broth dilution assay (above). PAS resistant isolates were then frozen at -70oC
until use.

8.16 DNA Extraction from PAS-Resistant Isolates
DNA from the PAS strains were isolated using TRI Reagent purchased from Sigma
Aldrich (St. Louis, MO) and following the TRI Reagent Protocol. Briefly, the PAS-resistant
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M. tuberculosis strains were grown in modified 7H10 broth with 10% OADC and 0.05%
Tween 80 for 7-10 days. The isolates were diluted to 1 X 107 CFU/ml and 1ml of the
isolates was placed into a sterile microfuge tube. The isolates were centrifuged for 10
minutes at 12,000RPM. The supernatant was removed and 1ml of TRI Reagent was
added to the pellet and vortexed. After standing at room temperature for 10 minutes
0.2ml of chloroform was added to the tubes. The tubes were shaken for 15 seconds and
allowed to stand for 10-15 minutes. The tubes were centrifuged for 15 minutes at
12,000RPM at 4oC.

The aqueous phase (containing RNA) was removed and

discarded. To the interphase and organic phase (DNA and protein) 0.3ml of 100%
ethanol was added, mixed by inversion and allowed to stand for 2-5 minutes. The tubes
were centrifuged in a cold room for 5 minutes at 6,000RPM. The supernatant was
discarded and the pellet containing the DNA was washed twice with a 0.1Mtrisodium
citrate:10% ethanol solution. Between washing steps the pellets we allowed to sit at room
temperature for 30 minutes and then centrifuged at 6,000RPM for 5 minutes. After the
final wash the pellet was resuspended in 1ml of 75% ethanol. Samples were plated on
7H10 agar to ensure that no viable M. tuberculosis remained.

8.17 Next Generation Genomics Sequencing
One nanogram of genomic DNA was used for cDNA library preparation using the Nextera
XT Library Preparation Kit (Illumina, Inc) according to the manufacturer’s protocol. The
libraries were sequenced on the MiSeq using v2 2x250 base pair kit (Illumina, Inc). The
genome was assembled using CLC Workbench and annotated using the Rast Server.22
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8.18 HPLC Analysis of FDTS Reaction
The reaction mixture was analyzed at different time points on a Shimadzu HPLC system
using a reversed phase Phenomenex C 18 column (4.6 x 250 mm, 5 µm), with mobile
phase A { 5 mM potassium phosphate (pH 7.0), 5 mM tetrabutylammonium dihydrogen
phosphate, and 5% acetonitrile} and mobile phase B ( acetonitrile).The flow rate was 1
ml/min and the gradient was as follows: 100% A, 0-25 min; 100-10% A, 25-29 min; 10100% A, 29-31 min; 100% A, 31-40 min. The injection volume for each sample was 50
µL and the autosampler was set at 4°C. The standard solution of dUMP and dTMP were
run to assign the retention times and the elution was monitored at 260 nm.

8.19 Mycolic Acid Profile
The strain of M. tuberculosis Erdman was grown shaking at 37°C in Middlebrook 7H9
broth (Difco) supplemented with albumin-dextrose-catalase and 0.05% Tween 80. At
O.D.600

nm

~ 0.32 the culture was divided into 100 µl aliquots and tested compounds

dissolved in DMSO were added in 0.36, 0.72 and 1.44 µg/ml final concentrations for
UCP1172 and 0.36 and 0.72 µg/ml final concentrations for PAS. The final concentration
of DMSO in each culture was kept 2 %. The cells grew 24 h statically in the presence of
the tested compounds. Then

14

C acetate (specific activity 106 mCi/mmol, ARC) was

added in the final concentration 1 μCi/mL and the cultures continued growing for next 24
hours.
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The lipids were extracted from 100 µl culture aliquots as described earlier with minor
modifications.23 Briefly, the cultures were transferred to 3 ml chloroform: methanol (2:1)
and the mixtures were incubated at 65°C for 2 h. After cooling down, 400 µl of water was
added, the mixtures were mixed and centrifuged 15 min at 1 000 x g at room temperature.
The organic phases were removed to the clean tube, dried under N2 and dissolved in
30 μl chloroform: methanol (2:1). 5 μl of each lipid sample were quantified by scintillation
counting and 5 μl were loaded on the thin-layer chromatography (TLC) silica gel plates
F254 (Merck). Lipids were separated in chloroform: methanol: water [20:4:0.5] and the
plates were exposed to autoradiography film Biomax MR (Kodak) at -80°C for 7 days.
Methyl esters of fatty acids (FAME) and mycolic acids (MAME) were prepared from
another 100 μl culture aliquots as previously described (B. Phetsuksiri, A.R. Baulard, A.M.
Cooper, D.E. Minnikin, J.D. Douglas, G.S. Besra, P.J. Brennan Antimycobacterial
activities of isoxyl and new derivatives through the inhibition of mycolic acid
synthesis Antimicrob. Agents Chemother., 43 (1999), pp. 1042–1051). Dried extracts
were dissolved in 30 μl chloroform: methanol (2:1), 5 μl of each sample were quantified
by scintillation counting and 5 μl were loaded on TLC plates and different forms of methyl
esters were separated in n-hexane/ethyl acetate [95:5], 3 runs and detected by
autoradiography. Alternatively, methyl ester derivatives were loaded on TLC plates
impregnated in 5% AgNO3 and activated at 100°C for 1h and separated in the same
solvent. The plates were exposed to autoradiography film Biomax MR (Kodak) at -80°C
for 7 days.
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Appendix A

Organism
Mtb Erdmann
Mtb 5
Mtb 365
Mtb 276
Mtb 352
Mtb 56

Resistance Pattern of Organisms Tested Against DHFR Inhibitors

INH
0.06
2
4
0.25
1
2

RIF
0.004
8
64
0.015
0.001
32

MIC (µg/ml)
Ethambutol
1

Streptomycin

32
4
1,
32

32
0.25
0.25
32
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Moxifloxacin
0.06
1
0.06

Appendix B Crystallography Data Collection and Refinement Statistics
Complex

MtbDHFR:NADPH:1172

MtbDHFR:NADPH:1175

PDB ID

6DDP

6DDS

Beamline

SSRL 14-1

SSRL 14-1

Space group

P1

P1

a, b, c (Å)

57.77, 60.55, 60.63

59.20, 60.80, 60.72

a, b, g (°)

90.04, 90.02, 90.03

90.15, 89.93, 90.01

Resolution (Å)

34.42-1.461

27.00-1.72

Highest resolution shell (Å)

1.53-1.46

1.75-1.72

Completeness%

99.4 (98.2)

96.8 (93.9)

Rsym

0.020 (0.239)

0.028 (0.128)

Rpim

0.020 (0.239)

0.028 (0.128)

Rmeas

0.029 (0.338)

0.040 (0.182)

Redundancy

1.5 (1.4)

1.6 (1.5)

Mean I/s(I)

13.8 (3.0)

9.0 (4.3)

Resolution (Å)

34.42-1.461

27.00-1.72

No. of reflections

118402

70016

Rfactor/Rfree

0.2029/0.2253

0.1817/0.2056

5652

5957

0.007

0.008

1.29

1.27

Data collection statistics

Cell dimensions

Refinement statistics

No. of atoms
(protein, ligand, solvent)
rmsd bond length (Å)
rmsd bond angle (°)

Ramachandran plot analysis (%)
Most favored

98.1

97.3

Outliers

0.2

0.3
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Complex

MtbDHFR:NADPH:PASOX

HuDHFR:NADPH:1172

PDB ID

6DDW

6DE4

Beamline

SSRL 14-1

SSRL 14-1

Space group

P41

C2221

a, b, c (Å)

60.43, 60.43, 58.95

104.61, 104.66, 144.33

a, b, g (°)

90, 90, 90

90, 90, 90

Resolution (Å)

42.22-1.40

42.37-2.41

Highest resolution shell (Å)

1.44-1.40

2.47-2.41

Completeness%

86.7 (43.5)

99.7 (97.2)

Rsym

0.013 (0.151)

0.082 (0.779)

Rpim

0.013 (0.151)

0.031 (0.297)

Rmeas

0.018 (0.214)

0.088 (0.835)

Redundancy

2 (1.9)

7.7 (7.7)

Mean I/s(I)

24 (3.8)

16.4 (4.2)

Resolution (Å)

42.22-1.40

42.37-2.41

No. of reflections

36214

30735

Data collection statistics

Cell dimensions

Refinement statistics

Rfactor/Rfree
No. of atoms
(protein, ligand, solvent)
rmsd bond length (Å)
rmsd bond angle (°)

0.1812/0.2205
1523

3420

0.007

0.008

1.36

1.05

Ramachandran plot analysis (%)
Most favored

97.5

97.9

Outliers

0

0.3
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Complex

MtbRV2671:NADPH:1063

MtbDHFR:NADPH:1106

PDB ID

6DE5

5JA3

Beamline

NSLS AMX 17 D-1

SSRL 14-1

Space group

C2221

P1

a, b, c (Å)

70.44, 94.63, 75.49

59.61, 60.44, 60.47

a, b, g (°)

90, 90, 90

Resolution (Å)

56.52-2.30

Highest resolution shell (Å)

2.40-2.30

Completeness%

98 (98.2)

72.89 (75)

Rsym

0.091 (0.236)

0.034 (0.201)

Rpim

0.091 (0.236)

Rmeas

0.091 (0.236)

Redundancy

1.9 (1.8)

1.5 (1.4)

Mean I/s(I)

5.5 (3.3)

28.82 (4.17)

Resolution (Å)

56.52-2.30

34.72-1.81

No. of reflections

11313

55796

Rfactor/Rfree

0.1870/0.2477

0.2266/0.2617

No. of atoms
(protein, ligand, solvent)
rmsd bond length (Å)

1969

5331

rmsd bond angle (°)

1.23

Data collection statistics

Cell dimensions

34.72-1.81

Refinement statistics

0.010

Ramachandran plot analysis (%)
Most favored

95.5

95.55

Outliers

0.4

0.48
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